

CITATION REPORT

List of articles citing

Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study

DOI: 10.1007/s00270-009-9711-7

CardioVascular and Interventional Radiology, 2010, 33, 41-52

Source: <https://exaly.com/paper-pdf/47812384/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1204	Assessment and triage of hepatocellular carcinoma. 85-90		
1203	Chemoembolization for primary and metastatic liver cancer. 2010 , 16, 156-62		31
1202	[Interventional radiological treatment of hepatocellular carcinoma]. 2010 , 151, 1204-8		
1201	Interventional radiological treatment of hepatocellular carcinoma. 2010 , 17, 87-99		15
1200	Intra-arterial therapies for hepatocellular carcinoma: where do we stand?. 2010 , 17, 1234-46		70
1199	[Interventional procedures for hepatic metastases]. 2010 , 81, 542-50		4
1198	Traitements du carcinome hpatocellulaire non accessible ^ un traitement curatif: actualit\$. 2010 , 12, 615-622		
1197	Hepatocellular carcinoma [New trends. 2010 , 3, 113-118		
1196	Gastrointestinale Angiographie. 2010 , 5, 517-525		
1195	Locoregional intra-arterial therapies for unresectable intrahepatic cholangiocarcinoma. 2010 , 37, 110-7		29
1194	Transarterial chemoembolization, transarterial chemotherapy, and intra-arterial chemotherapy for hepatocellular carcinoma treatment. 2010 , 37, 89-93		34
1193	Subselective intra-arterial chemotherapy infusion in the treatment of hepatocellular carcinoma. 2010 , 37, 83-8		1
1192	Loco-regional treatment of hepatocellular carcinoma. 2010 , 52, 762-73		383
1191	Is it time to reconsider the BCLC/AASLD therapeutic flow-chart?. 2010 , 102, 868-76		23
1190	Inherited hepatocellular carcinoma. 2010 , 24, 725-34		17
1189	Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus conference. 2010 , 12, 321-2		1
1188	Loco-regional interventional treatment of hepatocellular carcinoma: techniques, outcomes, and future prospects. 2010 , 23, 698-703		23

1187	An evidence-based multidisciplinary approach to the management of hepatocellular carcinoma (HCC): the Alberta HCC algorithm. 2010 , 24, 643-50	28
1186	Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved?. 2010 , 15 Suppl 4, 42-52	121
1185	The intermediate hepatocellular carcinoma stage: Should treatment be expanded?. 2010 , 42 Suppl 3, S258-63	46
1184	Hepatocellular carcinoma: A global view. 2010 , 7, 448-58	992
1183	Which transarterial therapy is best for hepatocellular carcinoma?--the evidence to date. 2010 , 53, 588	12
1182	[Nonsurgical management of hepatocellular carcinoma]. 2010 , 14, 469-73	
1181	Comparative study of chemoembolization loadable beads: in vitro drug release and physical properties of DC bead and hepasphere loaded with doxorubicin and irinotecan. 2010 , 21, 1084-90	112
1180	Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial. 2011 , 197, W562-70	136
1179	Advances in regional chemotherapy of the liver. 2011 , 8, 1057-69	15
1178	The use of transarterial chemoembolization in the treatment of unresectable hepatocellular carcinoma: a response to the Cochrane Collaboration review of 2011. 2011 , 22, 1693-6	24
1177	Hepatocellular carcinoma: locoregional and targeted therapies. 2011 , 40, 599-610	6
1176	Locoregional therapy for hepatocellular carcinoma. 2011 , 15, 395-421, vii-x	14
1175	Intraprocedural transcatheter intra-arterial perfusion MRI as a predictor of tumor response to chemoembolization for hepatocellular carcinoma. 2011 , 18, 828-36	16
1174	Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. 2011 , 22, 1545-52	156
1173	Comparison of doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma. 2011 , 53, 246-253	27
1172	Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. 2011 , 140, 497-507.e2	473
1171	Randomised controlled trial of lipiodol transarterial chemoembolisation with or without amiodarone for unresectable hepatocellular carcinoma. 2011 , 43, 905-11	7
1170	Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia. 2011 , 81 Suppl 1, 158-64	93

1169	DC Bead embolic drug-eluting bead: clinical application in the locoregional treatment of tumours. 2011 , 8, 153-69	54
1168	Targeted therapies for hepatocellular carcinoma. 2011 , 140, 1410-26	360
1167	Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma. 2011 , 22, 1697-705	81
1166	Chimio-embolisation trans-artielle des carcinomes hpatocellulaires par billes chargès ^ la doxorubicine. Transarterial chemoembolization of hepatocellular carcinoma with doxorubicin eluting beads. 2011 , 42, 21-31	
1165	[Radioembolisation for hepatocellular carcinoma]. 2011 , 15, 64-8	2
1164	Experience Using Doxorubicin-Loaded DC Beads During Hepatic Chemoembolisation. 2011 , 35, 172-179	
1163	Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. 2011 , 29, 3960-7	243
1162	Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation. 2011 , 54, 695-704	129
1161	Embolization of hepatocellular carcinoma with drug-eluting beads: doxorubicin tissue concentration and distribution in patient liver explants. 2011 , 55, 1332-8	121
1160	Embolization of hepatocellular carcinoma with drug-eluting beads: new insight into the biologic effects of tumor ablation. 2011 , 55, 1169-70	4
1159	Hepatocellular carcinoma. 2011 , 365, 1118-27	3015
1158	Carcinoma hepatocelular. 2011 , 15, 1-9	
1157	Transarterial Chemoembolization of Child-A hepatocellular carcinoma: drug-eluting bead TACE (DEB TACE) vs. TACE with cisplatin/lipiodol (cTACE). 2011 , 17, CR189-95	51
1156	Imaged Guided Transarterial Chemoembolization with Drug-Eluting Beads Loaded with Doxorubicin (DEBDOX) for Hepatic Metastases from Melanoma: Early Outcomes from a Multi-Institutional Registry. 2011 , 77, 93-98	11
1155	Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma. 2011 , 18, 228-40	44
1154	Hepatocellular carcinomas smaller than 4 cm supplied by the intercostal artery: can we predict which intercostal artery supplies the tumor?. 2011 , 12, 693-9	8
1153	[Economic impact of transarterial chemoembolization with drug eluting beads in the treatment of hepatocellular carcinoma]. 2011 , 98, 671-8	11
1152	Who could Benefit from Chemoembolisation?. 2011 , 125-135	

1151	Reactivated hepatitis B due to medical interventions: the clinical spectrum expands. 2011 , 16, 947-9		1
1150	Personalized medicine in hepatocellular carcinoma: rationale and clinical data. 2011 , 1, 1403-1411		1
1149	Carcinome h�patocellulaire. 2011 , 6, 1-9		
1148	Primary Malignant Neoplasms of the Liver. 2011 , 681-703		4
1147	The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma. 2011 , 34, 205-13		81
1146	[Comparison of doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma]. 2011 , 53, 246-53		35
1145	Chemoembolization for hepatocellular carcinoma. 2011 , 46, 105-14		4
1144	Hepatic arterial infusion of doxorubicin-loaded microsphere for treatment of hepatocellular cancer: a multi-institutional registry. 2011 , 213, 493-500		15
1143	Chemoembolization agents for cancer treatment. 2011 , 44, 1-10		47
1142	[Experience using doxorubicin-loaded DC Beads� during hepatic chemoembolisation]. 2011 , 35, 172-9		3
1141	Transcatheter arterial chemoembolization with docetaxel-loaded microspheres controls heavily pretreated unresectable liver metastases from colorectal cancer: a case study. 2011 , 16, 613-6		6
1140	Arterial therapies of non-colorectal cancer metastases to the liver (from chemoembolization to radioembolization). 2011 , 36, 671-6		21
1139	Current concepts in transarterial chemoembolization of hepatocellular carcinoma. 2011 , 36, 677-83		18
1138	Transcatheter arterial chemoembolization for liver cancer: is it time to distinguish conventional from drug-eluting chemoembolization?. <i>CardioVascular and Interventional Radiology</i> , 2011 , 34, 37-49	2.7	85
1137	Percutaneous transumbilical portal vein embolization in a patient with a ruptured hepatocellular carcinoma supplied by the portal vein. <i>CardioVascular and Interventional Radiology</i> , 2011 , 34 Suppl 2, S214-7	2.7	4
1136	Safety profile of sequential transcatheter chemoembolization with DC Bead�results of 237 hepatocellular carcinoma (HCC) patients. <i>CardioVascular and Interventional Radiology</i> , 2011 , 34, 774-85	2.7	102
1135	Severe complication after a doxorubicin-eluting-bead embolization: surgical management and pathological findings. <i>CardioVascular and Interventional Radiology</i> , 2011 , 34 Suppl 2, S186-9	2.7	2
1134	Transcatheter arterial chemoembolization with epirubicin-loaded superabsorbent polymer microspheres for 135 hepatocellular carcinoma patients: single-center experience. <i>CardioVascular and Interventional Radiology</i> , 2011 , 34, 557-65	2.7	47

1133	Hepatic arterial chemoembolization using drug-eluting beads in gastrointestinal neuroendocrine tumor metastatic to the liver. <i>CardioVascular and Interventional Radiology</i> , 2011 , 34, 566-72	2.7	48
1132	Hepatic arterial embolization with doxorubicin-loaded superabsorbent polymer microspheres in a rabbit liver tumor model. <i>CardioVascular and Interventional Radiology</i> , 2011 , 34, 1021-30	2.7	42
1131	The Editors' Medal 2011. <i>CardioVascular and Interventional Radiology</i> , 2011 , 34, 675-675	2.7	
1130	Hepatocellular carcinoma: prevention and therapy. 2011 , 13, 186-94		7
1129	Pulmonary artery chemoembolization in a sheep model: Evaluation of performance and safety of irinotecan eluting beads (DEB-IRI). 2011 , 98, 351-9		9
1128	Transcatheter arterial chemoembolization in combination with high-intensity focused ultrasound for unresectable hepatocellular carcinoma: a systematic review and meta-analysis of the chinese literature. 2011 , 37, 1009-16		10
1127	Chemoembolization of hepatocellular carcinoma with drug-eluting beads complicated by interstitial pneumonitis. 2011 , 28, 218-21		5
1126	Transarterial therapies for hepatocellular carcinoma. 2011 , 12, 1057-73		29
1125	Chemoembolization with drug-eluting beads complicated by intrahepatic biloma. 2011 , 28, 212-7		6
1124	Arterially directed therapies for hepatocellular carcinoma. 2011 , 197, W590-602		16
1123	Transcatheter intraarterial therapies: rationale and overview. 2011 , 259, 641-57		174
1122	Superselective transarterial chemoembolization for hepatocellular carcinoma: recent progression and perspective. 2011 , 81 Suppl 1, 105-10		7
1121	Drug delivery embolization systems: a physician's perspective. 2011 , 8, 1071-84		14
1120	A new tool to enhance the efficacy of chemoembolization to treat primary and metastatic hepatic tumors. 2011 , 8, 409-13		3
1119	Transarterial chemoembolization for hepatocellular carcinoma over three decades: current progress and perspective. 2012 , 42, 247-55		37
1118	Local-regional treatment of hepatocellular carcinoma. 2012 , 262, 43-58		264
1117	Transcatheter arterial chemotherapy using miriplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma. 2012 , 42, 175-82		14
1116	How I do it: triaging patients with hepatocellular carcinoma. 2012 , 29, 64-8		1

1115	Chemoembolization practice patterns and technical methods among interventional radiologists: results of an online survey. 2012 , 198, 692-9	53
1114	Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2012 , 23 Suppl 7, vii41-8	270
1113	Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics. 2012 , 4, 19-37	151
1112	Contemporary strategies in the management of hepatocellular carcinoma. 2012 , 2012, 154056	4
1111	Hepatocellular carcinoma: natural history, current management, and emerging tools. 2012 , 6, 207-19	45
1110	Chemoembolization in patients with hepatocellular carcinoma. 2012 , 1, 41-50	70
1109	How to improve treatment outcomes for hepatocellular carcinoma of intermediate and advanced stage. 2012 , 30, 598-602	16
1108	Perspectives on the design of clinical trials combining transarterial chemoembolization and molecular targeted therapy. 2012 , 1, 168-76	13
1107	Enhancement patterns of hepatocellular carcinoma after transarterial chemoembolization using drug-eluting beads on arterial phase CT images: a pilot retrospective study. 2012 , 199, 349-59	19
1106	Elaborate designs with artisan spirit to treat liver cancer in Japan. 2012 , 53, 463-485	
1105	Development of a combination drug-eluting bead: towards enhanced efficacy for locoregional tumour therapies. 2012 , 23, 355-69	16
1104	Magnetic resonance-guided laser-induced thermotherapy in patients with oligonodular hepatocellular carcinoma: long-term results over a 15-year period. 2012 , 46, 796-801	17
1103	Hepatocarcinoma. 2012 , 11, 693-703	
1102	Management of HCC. 2012 , 56 Suppl 1, S75-87	438
1101	Hepatocellular carcinoma. 2012 , 379, 1245-55	3423
1100	Emerging roles for biomaterials in the treatment of liver disease. 2012 , 9, 181-8	
1099	Current status of embolic agents for liver tumor embolization. 2012 , 17, 306-15	49
1098	Lokalablative Therapien zur Behandlung des hepatozellulären Karzinoms. 2012 , 7, 407-412	

1097	Systemische Therapie des hepatozellulären Karzinoms. 2012 , 7, 413-418	
1096	Acute ischemic cholecystitis after transarterial chemoembolization with drug-eluting beads. 2012 , 36, 861-4	6
1095	Ethiodized oil uptake does not predict doxorubicin drug delivery after chemoembolization in VX2 liver tumors. 2012 , 23, 265-73	38
1094	Multidisciplinary management of hepatocellular carcinoma. 2012 , 10, 354-62	41
1093	Interventional radiologic treatment of hepatocellular carcinoma-a cost analysis from the payer perspective. 2012 , 23, 306-14	36
1092	Value of noncontrast CT immediately after transarterial chemoembolization of hepatocellular carcinoma with drug-eluting beads. 2012 , 23, 1031-5	21
1091	Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. 2012 , 57, 1244-50	173
1090	ACR Appropriateness Criteria radiologic management of hepatic malignancy. 2012 , 9, 919-25	4
1089	Chemoembolization for hepatocellular carcinoma. 2012 , 39, 503-9	85
1088	Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. 2012 , 23, 287-94	135
1087	Hepatocellular Carcinoma. 2012 , 1005-1031	1
1086	Analysis of survival predictors in a prospective cohort of patients undergoing transarterial chemoembolization for hepatocellular carcinoma in a single Canadian centre. 2012 , 14, 162-70	10
1085	Liver/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: lipiodol vs. drug-eluting beads. 2012 , 56, 609-17	130
1084	EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. 2012 , 56, 908-43	4465
1083	Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma. 2012 , 56, 1336-42	127
1082	Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. 2012 , 56, 1330-5	354
1081	Reply to: Do EASL and mRECIST responses have independent effects on survival in hepatocellular carcinoma patients treated with transarterial embolization? 2012 , 57, 225-226	
1080	TACE with or without systemic therapy?. 2012 , 56, 1224-5	19

1079	EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. 2012 , 48, 599-641	356
1078	Transarterial chemoembolization in very early and early-stage hepatocellular carcinoma patients excluded from curative treatment: a prospective cohort study. 2012 , 81, 1173-8	70
1077	Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial. 2012 , 13, 144	23
1076	Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib. 2012 , 263, 590-9	154
1075	State of the art Hepatocellular carcinoma. 2012 , 10, 20-22	
1074	Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy. 2012 , 83, 216-24	37
1073	Locoregional radiological treatment for hepatocellular carcinoma; Which, when and how?. 2012 , 38, 54-62	49
1072	Treatment of hepatocellular carcinoma (HCC) by intra-arterial infusion of radio-emitter compounds: trans-arterial radio-embolisation of HCC. 2012 , 38, 641-9	28
1071	Midterm follow-up after DC-BEAD+TRACE of hepatocellular carcinoma (HCC). 2012 , 81, 3857-61	10
1070	Hepatocellular Carcinoma. 2012 , 141-157	
1069	Screening and Management of Hepatocellular Carcinoma: The Australian Perspective. 2012 , 11, 197-205	
1068	Response rate and clinical outcome of HCC after first and repeated cTACE performed "on demand". 2012 , 57, 1258-67	100
1067	Radiopaque drug-eluting beads for transcatheter embolotherapy: experimental study of drug penetration and coverage in swine. 2012 , 23, 257-64.e4	87
1066	Phase I/II multicenter study of transarterial chemoembolization with a cisplatin fine powder and porous gelatin particles for unresectable hepatocellular carcinoma: Japan Interventional Radiology in Oncology Study Group Study 0401. 2012 , 23, 1278-85	14
1065	Safety and feasibility of same-day discharge of patients with unresectable hepatocellular carcinoma treated with doxorubicin drug-eluting bead transcatheter chemoembolization. 2012 , 23, 1286-93.e1 ²²	
1064	Antitumour effect of sesquiterpene (+)-chabranol on four human cancer cell lines by inducing apoptosis and autophagy. 2012 , 40, 1644-53	3
1063	Systemtherapie des Leberzellkarzinoms. 2012 , 15, 26-30	
1062	Irinotecan loaded in eluting beads: preclinical assessment in a rabbit VX2 liver tumor model. <i>CardioVascular and Interventional Radiology</i> , 2012 , 35, 1448-59	2.7 36

1061	Transcatheter treatment of hepatocellular carcinoma with Doxorubicin-loaded DC Bead (DEBDOX): technical recommendations. <i>CardioVascular and Interventional Radiology</i> , 2012 , 35, 980-5	2.7	206
1060	Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: five-year survival analysis. <i>CardioVascular and Interventional Radiology</i> , 2012 , 35, 1119-28	2.7	139
1059	Quality-improvement guidelines for hepatic transarterial chemoembolization. <i>CardioVascular and Interventional Radiology</i> , 2012 , 35, 765-74	2.7	54
1058	Hepatic arterial embolization for unresectable hepatocellular carcinomas: do technical factors affect prognosis?. 2012 , 30, 560-6		46
1057	Current status of hepatocellular carcinoma treatment in Japan: transarterial chemoembolization. 2012 , 32 Suppl 2, 3-13		19
1056	Chimioembolisations et chimiothérapies intra-artérielles hépatiques. 2012 , 119-136		
1055	Hepatic arterial therapy with drug-eluting beads in the management of metastatic pancreatic carcinoma to the liver: a multi-institutional registry. 2012 , 2012, 168303		7
1054	Hepatic arterial therapy with drug-eluting beads in the management of metastatic bronchogenic carcinoma to the liver: a multi-institutional registry. 2012 , 2012, 292131		2
1053	[Treatment of Hepatocellular Carcinoma with Drug-eluting Beads Chemoembolization and Liver Transplantation]. 2012 , 60, 335-8		
1052	Embolization of liver tumors: Past, present and future. 2012 , 4, 405-12		54
1051	Comparison of epirubicin-iodized oil suspension and emulsion for transcatheter arterial chemoembolization in VX2 tumor. 2012 , 2012, 961986		8
1050	Hepatocellular carcinoma: initial tumour response after short-term and long-interval chemoembolization with drug-eluting beads using modified RECIST. 2012 , 24, 1325-32		13
1049	Interventional therapies for hepatocellular carcinoma. 2012 , 12, 79-88		23
1048	Stereotactic body radiation therapy in hepatocellular carcinoma and cirrhosis: evaluation of radiological and pathological response. 2012 , 105, 692-8		60
1047	Hepatic artery embolization and chemoembolization of liver tumors. 2012 , 1344-1361.e3		
1046	Liver-directed therapies in liver metastases from neuroendocrine tumors of the gastrointestinal tract. 2012 , 7, 107-16		20
1045	Hepatocellular carcinoma: MR staging and therapeutic decisions. 2012 , 37, 231-8		1
1044	Is there any benefit from expanding the criteria for the resection of hepatocellular carcinoma in cirrhotic liver? Experience from a developing country. 2012 , 36, 1657-65		12

1043	Tumor response and apoptosis of N1-S1 rodent hepatomas in response to intra-arterial and intravenous benzamide riboside. <i>CardioVascular and Interventional Radiology</i> , 2012 , 35, 645-52	2.7	4
1042	Switching the loaded agent from epirubicin to cisplatin: salvage transcatheter arterial chemoembolization with drug-eluting microspheres for unresectable hepatocellular carcinoma. <i>CardioVascular and Interventional Radiology</i> , 2012 , 35, 555-62	2.7	21
1041	Hepatocellular carcinoma: computed-tomography-guided high-dose-rate brachytherapy (CT-HDRBT) ablation of large (5-7 cm) and very large (>7 cm) tumours. 2012 , 22, 1101-9		50
1040	Conventional transarterial chemoembolisation in combination with sorafenib for patients with hepatocellular carcinoma: a pilot study. 2012 , 22, 1214-23		41
1039	Austrian Joint ECR-ECIR-EHO-ASSO position statement on the use of transarterial chemoembolization (TACE) in hepatocellular carcinoma. 2012 , 124, 104-10		12
1038	Systemtherapie des Leberzellkarzinoms. 2012 , 18, 602-610		
1037	Chimioembolisation et hpatocarcinome: pour quel type de patient ?. 2012 , 14, 174-178		
1036	Optimal outcomes for liver-dominant metastatic breast cancer with transarterial chemoembolization with drug-eluting beads loaded with doxorubicin. 2012 , 132, 753-63		28
1035	Locoregional drug delivery using image-guided intra-arterial drug eluting bead therapy. 2012 , 161, 338-50		87
1034	Radiological response predicts survival following transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma. 2012 , 35, 1343-50		70
1033	Severity and timing of progression predict refractoriness to transarterial chemoembolization in hepatocellular carcinoma. 2012 , 27, 1051-6		43
1032	Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. 2012 , 118, 147-56		217
1031	Interventional radiological treatment of hepatocellular carcinoma: an update. 2012 , 74, 91-9		13
1030	[Transarterial ablation of hepatocellular carcinoma. Status and developments]. 2012 , 52, 44-55		7
1029	Chemoembolization via branches from the splenic artery in patients with hepatocellular carcinoma. <i>CardioVascular and Interventional Radiology</i> , 2012 , 35, 90-6	2.7	8
1028	Spontaneous liver rupture after treatment with drug-eluting beads. <i>CardioVascular and Interventional Radiology</i> , 2012 , 35, 198-202	2.7	11
1027	Anti-proliferative and pro-apoptotic effect of carvacrol on human hepatocellular carcinoma cell line HepG-2. 2012 , 64, 43-51		103
1026	Imaging assessment of hepatocellular carcinoma response to locoregional and systemic therapy. 2013 , 201, 80-96		62

1025	Antitumor effect of miriplatin-lipiodol suspension/emulsion using a VX2 liver tumor model. 2013 , 31, 662-7		2
1024	Imaging features following transarterial chemoembolization and radiofrequency ablation of hepatocellular carcinoma. 2013 , 34, 336-51		9
1023	Lipiodol trans-arterial chemoembolization of hepatocellular carcinoma with idarubicin: first experience. <i>CardioVascular and Interventional Radiology</i> , 2013 , 36, 1039-46	2.7	18
1022	Predictive factors of downstaging of hepatocellular carcinoma beyond the Milan criteria treated with intra-arterial therapies. <i>CardioVascular and Interventional Radiology</i> , 2013 , 36, 433-9	2.7	27
1021	Phase II study of chemoembolization with drug-eluting beads in patients with hepatic neuroendocrine metastases: high incidence of biliary injury. <i>CardioVascular and Interventional Radiology</i> , 2013 , 36, 449-59	2.7	69
1020	Supraumbilical subcutaneous fat necrosis after transcatheter arterial chemoembolization with drug-eluting beads: case report and review of the literature. <i>CardioVascular and Interventional Radiology</i> , 2013 , 36, 276-9	2.7	8
1019	Hepatotoxicity after transarterial chemoembolization and transjugular intrahepatic portosystemic shunt: do two rights make a wrong?. 2013 , 24, 68-73		24
1018	Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC). 2013 , 33, 327-37		52
1017	Factors affecting survival following chemoembolization with doxorubicin-eluting microspheres for inoperable hepatocellular carcinoma. 2013 , 24, 257-65		8
1016	Optimal measurement modality and method for evaluation of responses to transarterial chemoembolization of hepatocellular carcinoma based on enhancement criteria. 2013 , 24, 316-25		29
1015	Liver Intervention: Angiography. 2013 , 969-982		
1014	Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma. 2013 , 24, 307-15		57
1013	Alginate-lanthanide microspheres for MRI-guided embolotherapy. 2013 , 9, 4681-7		25
1012	A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma. 2013 , 108, 1252-9		99
1011	Management of Hepatocellular Carcinoma. 2013 , 544-551		
1010	The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. 2013 , 57, 2261-73		230
1009	Multidisciplinary approaches to intrahepatic cholangiocarcinoma. 2013 , 119, 3929-42		92
1008	Transarterial chemoembolization of hepatocellular carcinoma. Agents and drugs: an overview. Part 1. 2013 , 10, 679-90		22

1007	[Transarterial chemoembolisation in hepatocellular carcinoma]. 2013 , 163, 123-7	3
1006	Doxorubicin-loaded drug-eluting beads (DC Bead®) for use in transarterial chemoembolization: a stability assessment. 2013 , 19, 65-74	20
1005	Transarterial therapies for hepatocellular carcinoma (HCC): a long way towards standardization. 2013 , 58, 194	3
1004	How to decide about liver transplantation in patients with hepatocellular carcinoma: size and number of lesions or response to TACE?. 2013 , 59, 279-84	87
1003	Safety and efficacy of drug-eluting bead chemoembolization for hepatocellular carcinoma: comparison of small-versus medium-size particles. 2013 , 24, 301-6	65
1002	Chemoembolization and radioembolization for hepatocellular carcinoma. 2013 , 11, 604-11; quiz e43-4	59
1001	Objective assessment of transcatheter arterial chemoembolization angiographic endpoints: preliminary study of quantitative digital subtraction angiography. 2013 , 24, 667-71	14
1000	Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate. 2013 , 58, 609-18	112
999	Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma. 2013 , 45, 712-23	128
998	Hepatic embolotherapy in interventional oncology: technology, techniques, and applications. 2013 , 68, 1-15	30
997	Outcomes of additional treatment for patients with infiltrative hepatocellular carcinoma. 2013 , 11, 1673	1
996	Result and cost of hepatic chemoembolisation with drug eluting beads in 21 patients. 2013 , 94, 53-9	9
995	Résultat et coût de la chimioembolisation hépatique avec des billes chargées chez 21 patients. 2013 , 94, 52-59	1
994	Intratumoral gas in hepatocellular carcinoma following transarterial chemoembolization: associated factors and clinical impact. 2013 , 24, 1623-31	6
993	Multivariate analysis of prognostic factors for survival following doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. 2013 , 24, 647-54	14
992	Use of Lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: a review. 2013 , 88, 530-49	131
991	Cancer concepts and principles: primer for the interventional oncologist-part II. 2013 , 24, 1167-88	20
990	HBV infection and hepatocellular carcinoma. 2013 , 17, 375-97	33

989	Single-center comparison of three chemoembolization regimens for hepatocellular carcinoma. 2013 , 24, 266-73		21
988	Modified RECIST to assess tumor response after transarterial chemoembolization of hepatocellular carcinoma: CT-pathologic correlation in 178 liver explants. 2013 , 82, e212-8		66
987	New progress of non-surgical treatments for hepatocellular carcinoma. 2013 , 30, 381		20
986	Transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: recent progression and perspective. 2013 , 84 Suppl 1, 28-33		10
985	Combining transarterial chemoembolization with radiofrequency ablation for hepatocellular carcinoma: one step forward?. 2013 , 31, 406-8		14
984	Minimally invasive therapies for hepatic malignancy. 2013 , 50, 146-79		5
983	In vitro and in vivo evaluation of biodegradable embolic microspheres with tunable anticancer drug release. 2013 , 9, 6823-33		74
982	Embolisation devices from biomedical polymers for intra-arterial occlusion and drug delivery in the treatment of cancer. 2013 , 207-239e		3
981	Effectiveness and safety of doxorubicin loaded beads in hepatocellular carcinoma. 2013 , 35, 1105-12		2
980	Toxicity of doxorubicin on pig liver after chemoembolization with doxorubicin-loaded microspheres: a pilot DNA-microarrays and histology study. <i>CardioVascular and Interventional Radiology</i> , 2013 , 36, 204-12	2.7	11
979	[Neoplastic lesions of the digestive tract: diagnosis and treatment through imaging]. 2013 , 78 Suppl 1, 19-21		
978	[Diagnosis of and therapy for hepatocellular carcinoma]. 2013 , 51, 1269-326		67
977	Intraprocedural C-arm dual-phase cone-beam CT: can it be used to predict short-term response to TACE with drug-eluting beads in patients with hepatocellular carcinoma?. 2013 , 266, 636-48		85
976	Intraarterial therapies for primary liver cancer: state of the art. 2013 , 13, 1157-67		12
975	Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses. 2013 , 269, 603-11		104
974	Combining locoregional therapies in the treatment of hepatocellular carcinoma. 2013 , 30, 74-81		14
973	mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE). 2013 , 24, 965-73		85
972	Mental status changes postchemoembolization: the role of inflammatory response. 2013 , 30, 219-22		

971	Chemoembolization of hepatocellular carcinoma. 2013 , 30, 3-11	131
970	90Y radioembolization versus chemoembolization in the treatment of hepatocellular carcinoma: an analysis of comparative effectiveness. 2013 , 2, 435-44	6
969	Recent advances in the treatment of hepatocellular carcinoma. 2013 , 29, 285-92	80
968	Improved drug targeting to liver tumors after intra-arterial delivery using superparamagnetic iron oxide and iodized oil: preclinical study in a rabbit model. 2013 , 48, 826-33	13
967	Intermediate hepatocellular carcinoma: current treatments and future perspectives. 2013 , 24 Suppl 2, ii24-9	59
966	Consider the perspectives: interventional radiology. 2013 , 47 Suppl, S43-6	
965	Chemopreventive Effect of Bauhinia Purpurea Against Chemically Induced Hepatocarcinogenesis via Amelioration of Oxidative Damage, Cell Proliferation and Induction of Apoptosis in Wistar Rats. 2013 , 20, 117-25	4
964	Transarterial embolization as neo-adjuvant therapy pretransplantation in patients with hepatocellular carcinoma. 2013 , 33, 944-9	43
963	Roles played by chemolipiodolization and embolization in chemoembolization for hepatocellular carcinoma: single-blind, randomized trial. 2013 , 105, 59-68	47
962	Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma: a European perspective. 2013 , 25, 639-51	27
961	Morbidity and mortality following transarterial liver chemoembolization in patients with hepatocellular carcinoma and synthetic hepatic dysfunction. 2013 , 19, 164-73	56
960	Preliminary investigation of the dissolution behavior, cytocompatibility, effects of fibrinogen conformation and platelet adhesion for radiopaque embolic particles. 2013 , 4, 89-113	3
959	Imaging appearance of treated hepatocellular carcinoma. 2013 , 5, 417-24	22
958	Recent advance in international management of hepatocellular carcinoma. 2013 , 56, 972	2
957	Drug-eluting bead transarterial chemoembolisation for unresectable hepatocellular carcinoma. 2013 ,	
956	Interventional radiology in liver cancer. 2013 , 22, 20120010	
955	Chemoembolization with drug-eluting microspheres (DEM-TACE) for hepatocellular carcinoma: single-center review of safety and efficacy. 2014 , 1, 187-93	3
954	Transarterial chemoembolization and bland embolization for hepatocellular carcinoma. 2014 , 20, 3069-77	52

953	Comparison of drug release and pharmacokinetics after transarterial chemoembolization using diverse lipiodol emulsions and drug-eluting beads. 2014 , 9, e115898	41
952	Transarterial chemoembolization for hepatocellular carcinoma: A review of techniques. 2014 , 6, 844-50	45
951	The role of interventional radiology in the management of hepatocellular carcinoma. 2014 , 21, e480-92	36
950	Hepatocellular carcinoma review: current treatment, and evidence-based medicine. 2014 , 20, 4115-27	288
949	Interventional treatment for unresectable hepatocellular carcinoma. 2014 , 20, 13453-65	33
948	Transarterial embolization with or without chemotherapy for advanced hepatocellular carcinoma: a systematic review. 2014 , 35, 8451-9	21
947	Anthracyclines. 2014 , 683-694	4
946	Hepatobiliary quiz-12 (2014). 2014 , 4, 376-9	
945	Doxorubicin -eluting beads in the treatment of liver carcinoma. 2014 , 15, 115-20	2
944	Systemic therapy for hepatocellular carcinoma. 2014 , 1, 23-38	
943	How does selective internal radiation therapy compare with and/or complement other liver-directed therapies. 2014 , 10, 105-9	1
942	Clinical appraisal of the recently proposed Barcelona Clinic Liver Cancer stage B subclassification by survival analysis. 2014 , 29, 787-93	45
941	Unresectable hepatocellular carcinoma: randomized controlled trial of transarterial ethanol ablation versus transcatheter arterial chemoembolization. 2014 , 270, 607-20	31
940	Idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma: results of the IDASPHERE phase I trial. 2014 , 39, 1301-13	41
939	Transarterial chemoembolisation and radioembolisation for the treatment of primary liver cancer and secondary liver cancer: a review of the literature. 2014 , 58, 341-52	38
938	Editorial: IDASPHERE phase I trial for chemoembolisation of HCC. 2014 , 40, 209-10	0
937	Re-evaluating transarterial chemoembolization for the treatment of hepatocellular carcinoma: Consensus recommendations and review by an International Expert Panel. 2014 , 34, 174-83	53
936	Emerging trends in hepatocellular carcinoma: focus on diagnosis and therapeutics. 2014 , 8, 71-6	105

935	Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC. 2014 , 203, W706-14		43
934	Treatment of intermediate stage hepatocellular carcinoma: a review of intrahepatic doxorubicin drug-delivery systems. 2014 , 5, 447-66		22
933	Conventional TACE and drug-eluting bead TACE as locoregional therapy before orthotopic liver transplantation: comparison of explant pathologic response. 2014 , 98, 781-7		28
932	Multimodality therapy and liver transplantation for hepatocellular carcinoma: a 14-year prospective analysis of outcomes. 2014 , 98, 100-6		18
931	Acute eosinophilic and neutrophilic pneumonia following transarterial chemoembolization with drug-eluting beads loaded with doxorubicin for hepatocellular carcinoma: a case report. 2014 , 88, 426-9		2
930	Prognostic factors for hepatocellular carcinoma recurrence. 2014 , 20, 5935-50		105
929	Transarterial therapy: an evolving treatment modality of hepatocellular carcinoma. 2014 , 20, 333-41		4
928	Multimodal treatment of hepatocellular carcinoma. 2014 , 25, 430-7		65
927	Medico-economic study of the management of hepatocellular carcinoma by chemo-embolization. 2014 , 95, 427-34		10
926	Safety and feasibility of same-day discharge of patients with hepatocellular carcinoma treated with transarterial chemoembolization with drug-eluting beads in a liver transplantation program. 2014 , 25, 1012-7		16
925	Advanced age is not a contraindication for liver resection in cases of large hepatocellular carcinoma. 2014 , 40, 214-9		8
924	Aide à la décision médico-économique pour la prise en charge du carcinome hépato-cellulaire par chimio-embolisation. 2014 , 95, 431-438		0
923	Safety and effectiveness of chemoembolization with drug-eluting beads for advanced-stage hepatocellular carcinoma. <i>CardioVascular and Interventional Radiology</i> , 2014 , 37, 381-7	2.7	51
922	Trends in utilization of transarterial treatments for hepatocellular carcinoma: results of a survey by the Italian Society of Interventional Radiology. <i>CardioVascular and Interventional Radiology</i> , 2014 , 37, 438-44	2.7	35
921	Chemoembolization of hepatocellular carcinoma with HepaSphere 30-60 µ. Safety and efficacy study. <i>CardioVascular and Interventional Radiology</i> , 2014 , 37, 165-75	2.7	77
920	Nonsurgical treatment for localized hepatocellular carcinoma. 2014 , 16, 373		11
919	[Therapy of hepatocellular carcinoma]. 2014 , 55, 23-4, 26-30		4
918	Hepatocellular carcinoma: diagnosis, management, and prognosis. 2014 , 23, 289-311		49

917	Hepatocellular carcinoma and other liver lesions. 2014 , 98, 103-18		14
916	Chemoembolization for hepatocellular carcinoma: 1-month response determined with apparent diffusion coefficient is an independent predictor of outcome. 2014 , 270, 747-57		41
915	Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. 2014 , 111, 255-64		349
914	Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma. 2014 , 29, 920-5		79
913	Image-guided interventions in oncology. 2014 , 23, 937-55		8
912	TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial. 2014 , 74, 947-54		51
911	Chemoembolization and radioembolization. 2014 , 28, 909-19		14
910	Investigation of hepatobiliary disposition of doxorubicin following intrahepatic delivery of different dosage forms. 2014 , 11, 131-44		20
909	Treatment of intermediate-stage hepatocellular carcinoma. 2014 , 11, 525-35		315
908	Transarterial chemoembolization using drug eluting beads and subsequent percutaneous MR-guided radiofrequency ablation in the therapy of intermediate sized hepatocellular carcinoma. 2014 , 83, 1793-8		15
907	Transarterial chemoembolization and sorafenib in hepatocellular carcinoma. 2014 , 14, 831-45		16
906	Chemoembolization of intermediate stage hepatocellular carcinomas: results from a Nordic tertiary liver cancer center. 2014 , 33, 322-9		5
905	Selective internal radiotherapy (SIRT) versus transarterial chemoembolization (TACE) for the treatment of intrahepatic cholangiocellular carcinoma (CCC): study protocol for a randomized controlled trial. 2014 , 15, 311		18
904	[Transarterial ablative therapy of hepatocellular carcinoma]. 2014 , 54, 685-93		0
903	Hepatocellular carcinomas within the Milan criteria: predictors of histologic necrosis after drug-eluting beads transarterial chemoembolization. <i>CardioVascular and Interventional Radiology</i> , 2014 , 37, 1018-26	2.7	12
902	Safety and efficacy of a circumferential clip-based vascular closure device in cirrhotic and coagulopathic patients with hepatocellular carcinoma after doxorubicin drug-eluting beads transarterial chemoembolization. <i>CardioVascular and Interventional Radiology</i> , 2014 , 37, 664-70	2.7	7
901	Transarterial therapies for primary liver tumors. 2014 , 23, 323-51		8
900	Combination of intra-arterial therapies and sorafenib: is there a clinical benefit?. 2014 , 119, 476-82		6

899	Advances in managing hepatocellular carcinoma. 2014 , 8, 175-89	8
898	Degradable starch microspheres versus ethiodol and doxorubicin in transarterial chemoembolization of hepatocellular carcinoma. 2014 , 25, 240-7	15
897	Drug-eluting beads loaded with antiangiogenic agents for chemoembolization: in vitro sunitinib loading and release and in vivo pharmacokinetics in an animal model. 2014 , 25, 379-87, 387.e1-2	26
896	Reply to the letters to the editor regarding the sequential ART-score. 2014 , 61, 177-8	2
895	Clinical significance of the best response during repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma. 2014 , 60, 1212-8	24
894	Comparison of characteristics and transarterial chemoembolization outcomes in patients with unresectable hepatocellular carcinoma and different viral etiologies. 2014 , 25, 371-8	8
893	Transcatheter arterial chemoembolization with doxorubicin-eluting superabsorbent polymer microspheres in the treatment of hepatocellular carcinoma: midterm follow-up. 2014 , 25, 248-55.e1	12
892	The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: a comprehensive and evidence-based comparison and review. 2014 , 120, 2824-38	179
891	Effects of γ radiation and accelerated aging on composition-structure-property relationships for radiopaque embolic microspheres. 2014 , 402, 84-90	3
890	Role of Transcatheter Intra-arterial Therapies for Hepatocellular Carcinoma. 2014 , 4, S112-21	22
889	The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: The Puri Recommendations. 2014 , 4, S3-S26	38
888	[Liver cancer: progress in diagnosis and treatments. Topics: VI. Progress in treatments of liver cancer; 3. Transarterial chemoembolization]. 2014 , 103, 87-92	2
887	How to define transarterial chemoembolization failure or refractoriness: a European perspective. 2014 , 3, 119-24	90
886	Hepatocellular Carcinoma: Current Concepts in Diagnosis, Staging and Treatment. 2014 , 1, 84-92	17
885	Delayed intratumoral hemorrhage after drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma. 2014 , 7, 739-45	2
884	Comparison of RECIST, mRECIST, and choi criteria for early response evaluation of hepatocellular carcinoma after transarterial chemoembolization using drug-eluting beads. 2014 , 38, 391-7	16
883	Section 3. Current status of downstaging of hepatocellular carcinoma before liver transplantation. 2014 , 97 Suppl 8, S10-7	20
882	Chemoembolization with DC Bead for the treatment of hepatocellular carcinoma: an update. 2014 , 1, 205-214	3

881	Rationale of transcatheter intra-arterial therapies of hepatic cancers. 2014 , 1, 285-291	2
880	Current role of transarterial chemoembolization and radioembolization in the treatment of metastatic colorectal cancer. 2014 , 1, 215-228	3
879	Unanticipated stabilization of zinc-silicate glasses by addition of lanthanum: Implications for therapeutic inorganic ion delivery systems. 2015 , 429, 83-92	5
878	Traitement radiologique du CHC : la radiologie interventionnelle au centre de la prise en charge. 2015 , 96, 180-191	
877	Medical interventions associated with HBV reactivation: Common and less common. 2015 , 5, 32-34	3
876	Treatment for hepatocellular carcinoma in Japan over the last three decades: Our experience and published work review. 2015 , 45, 59-74	64
875	Challenges of Clinical Research on Hepatocellular Carcinoma. 2015 , 33, 780-90	3
874	Arterial Therapies of Non-Colorectal Liver Metastases. 2015 , 31, 414-22	4
873	Transcatheter arterial chemoembolization as an examination method for hepatocellular carcinoma undetected by B-mode ultrasound, computed tomography and digital subtraction angiography: A case report. 2015 , 10, 1759-1762	4
872	Is drug-eluting-bead transcatheter arterial chemoembolization (TACE) associated with better tumor response than conventional TACE in a meta-analysis?: Authors' reply. 2015 , 45, 1260-1	
871	Chemoembolization of hepatocellular carcinoma with HepaSphere [®] 2015 , 2, 147-157	1
870	Hepatocellular Carcinoma. 2015 , 2146-2165	
869	Interventional Radiology. 2015 , 2909-2943	
868	Transarterial chemoembolization with drug-eluting beads is effective for the maintenance of the Milan-in status in patients with a small hepatocellular carcinoma. 2015 , 21, 1259-69	31
867	Is drug-eluting bead transcatheter arterial chemoembolization (TACE) associated with better tumor response than conventional TACE in meta-analysis?. 2015 , 45, 1258-9	3
866	Hepatocellular carcinoma tumor board: making sense of the technologies. 2015 , e213-20	1
865	2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma. 2015 , 16, 465-522	143
864	Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges. 2015 , 7, 787-98	119

863	Transarterial chemoembolization using gelatin sponges or microspheres plus lipiodol-doxorubicin versus doxorubicin-loaded beads for the treatment of hepatocellular carcinoma. 2015 , 16, 125-32	33
862	A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma. 2015 , 3, 221-252	1
861	MRI Findings and Prediction of Time to Progression of Patients with Hepatocellular Carcinoma Treated with Drug-eluting Bead Transcatheter Arterial Chemoembolization. 2015 , 30, 965-73	10
860	Addition of n-butyl cyanoacrylate to classic transarterial chemoembolization may improve the radiological response in patients with hepatocellular carcinoma. 2015 , 70, 781-9	1
859	Transarterial chemoembolization for hepatocellular carcinoma: an evidence-based review of its place in therapy. 2015 , 2, 123-9	13
858	Brazilian society of hepatology recommendations for the diagnosis and treatment of hepatocellular carcinoma. 2015 , 52 Suppl 1, 2-14	10
857	A lethal complication after transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. 2015 , 2015, 873601	6
856	Transarterial Embolization for Hepatocellular Carcinoma: A Comparison between Nonspherical PVA and Microspheres. 2015 , 2015, 435120	6
855	Hepatocellular carcinoma: Consensus, controversies and future directions. A report from the Canadian Association for the Study of the Liver Hepatocellular Carcinoma Meeting. 2015 , 29, 178-84	27
854	Current management of hepatocellular carcinoma: an Eastern perspective. 2015 , 21, 3826-42	39
853	Transarterial chemoembolisation in intermediate-stage hepatocellular carcinoma. Survey on clinical practice in hospitals in the Madrid Region. 2015 , 14, 207-217	1
852	Development of Intra-Arterial Chemoembolization for Various Types of Cancer in Humans. 2015 , 61, 220-227	
851	Drug-eluting bead transarterial chemoembolisation for unresectable hepatocellular carcinoma. 2015 ,	
850	New challenges in clinical research on hepatocellular carcinoma. 2016 , 108, 485-93	11
849	Oxaliplatin and 5-fluorouracil hepatic infusion with lipiodolized chemoembolization in large hepatocellular carcinoma. 2015 , 21, 3970-7	17
848	Diagnostic and therapeutic management of hepatocellular carcinoma. 2015 , 21, 12003-21	53
847	Current and future treatments for hepatocellular carcinoma. 2015 , 21, 8478-91	112
846	Transarterial chemoembolization using drug eluting beads for the treatment of hepatocellular carcinoma: Now and future. 2015 , 21, 344-8	21

845	Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system. 2015 , 21, 10327-35	79
844	Intermediate hepatocellular carcinoma: How to choose the best treatment modality?. 2015 , 7, 1184-91	16
843	Transarterial chemoembolization: Evidences from the literature and applications in hepatocellular carcinoma patients. 2015 , 7, 2009-19	62
842	Treatment of hepatocellular carcinoma: beyond international guidelines. 2015 , 35 Suppl 1, 129-38	47
841	Transarterial approaches to primary and secondary hepatic malignancies. 2015 , 12, 481-9	28
840	Tumor Markers AFP, AFP-L3, and DCP in Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization. 2015 , 89, 167-74	22
839	Radiological treatment of HCC: Interventional radiology at the heart of management. 2015 , 96, 625-36	12
838	Optimal methods for measuring eligibility for liver transplant in hepatocellular carcinoma patients undergoing transarterial chemoembolization. 2015 , 62, 1076-84	15
837	Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma. 2015 , 15, 465	77
836	Intermediate hepatocellular carcinoma: the role of transarterial therapy. 2015 , 2, 399-408	9
835	Intra-arterial chemoembolization with hepasphere 5000 for patients with unresectable hepatocellular carcinoma: Initial experience in Egyptian Liver Hospital. 2015 , 46, 957-965	
834	A Single-Center Retrospective Comparison of Doxorubicin-Loaded HepaSphere Transarterial Chemoembolization with Conventional Transarterial Chemoembolization for Patients with Unresectable Hepatocellular Carcinoma. 2015 , 26, 1622-9	18
833	Cost Accounting as a Tool for Increasing Cost Transparency in Selective Hepatic Transarterial Chemoembolization. 2015 , 26, 1820-6.e1	6
832	Management of vascular lake phenomenon on angiography during chemoembolization with superabsorbent polymer microspheres. 2015 , 33, 741-8	23
831	Trans-arterial chemoembolization with doxorubicin-eluting particles versus conventional trans-arterial chemoembolization in unresectable hepatocellular carcinoma: A study of effectiveness, safety and costs. 2015 , 57, 496-504	10
830	Surgical and Locoregional Therapy of HCC: TACE. 2015 , 4, 165-75	105
829	Survival analysis of proposed BCLC-B subgroups in hepatocellular carcinoma patients. 2015 , 35, 591-600	50
828	Idarubicin-loaded ONCOZENE drug-eluting embolic agents for chemoembolization of hepatocellular carcinoma: in vitro loading and release and in vivo pharmacokinetics. 2015 , 26, 262-70	26

827	BCLC stage B hepatocellular carcinoma and transcatheter arterial chemoembolization: a 20-year survey by the Italian Liver Cancer group. 2015 , 35, 223-31		30
826	Survival outcomes in patients with advanced hepatocellular carcinoma treated with drug-eluting bead chemoembolization. 2015 , 204, 440-7		15
825	Radiofrequency ablation plus drug-eluting beads transcatheter arterial chemoembolization for the treatment of single large hepatocellular carcinoma. 2015 , 47, 242-8		36
824	Engineering Biomaterial-Drug Conjugates for Local and Sustained Chemotherapeutic Delivery. 2015 , 26, 1212-23		23
823	Immediate post-doxorubicin drug-eluting beads chemoembolization Mr Apparent diffusion coefficient quantification predicts response in unresectable hepatocellular carcinoma: A pilot study. 2015 , 42, 981-9		19
822	Hepatocellular carcinoma. 2015 , 94-104		
821	Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study. 2015 , 30, 1167-74		14
820	Trans-arterial p53-gene-embolization with gelatin sponge microparticles for hepatocellular carcinoma with BCLC stage B: single-center experience. 2015 , 71, 99-104		9
819	Randomized comparison of selective internal radiotherapy (SIRT) versus drug-eluting bead transarterial chemoembolization (DEB-TACE) for the treatment of hepatocellular carcinoma. <i>CardioVascular and Interventional Radiology</i> , 2015 , 38, 352-60	2.7	63
818	Sunitinib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study. 2015 , 36, 183-91		3
817	Untethered magnetic millirobot for targeted drug delivery. 2015 , 17, 9962		24
816	Preventative effects of prostaglandin E1 in combination with iodized olive oil on liver fibrosis after transcatheter arterial chemoembolization in a rabbit model of CCL4-induced liver fibrosis. 2015 , 93, 451-7		6
815	Chimioembolisation des carcinomes h�patocellulaires : une vieille m�thode au go�t du jour. 2015 , 96, 162-171		
814	Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results. 2015 , 277, 594-603		26
813	Treatment of Liver Cancer. 2015 , 5, a021535		144
812	Transarterial hepatic chemoembolization with 70-150 �m drug-eluting beads: assessment of clinical safety and liver toxicity profile. 2015 , 26, 965-71		23
811	Liver cancer: Approaching a personalized care. 2015 , 62, S144-56		175
810	Transarterial chemoembolization for hepatocellular carcinoma: An old method, now flavor of the day. 2015 , 96, 607-15		18

809	Locoregional therapy of hepatocellular carcinoma. 2015 , 19, 401-20		22
808	Trans-arterial chemoembolization with doxorubicin-eluting particles versus conventional trans-arterial chemoembolization in unresectable hepatocellular carcinoma: A study of effectiveness, safety and costs. 2015 , 57, 496-504		15
807	Safety and efficacy of 70-150 μ m and 100-300 μ m drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma. 2015 , 26, 516-22		45
806	New treatment modalities for hepatocellular cancer. 2015 , 17, 442		7
805	Transplantation for Primary Hepatic Malignancy. 2015 , 189-204		0
804	[Targeted radiological therapy of liver tumors]. 2015 , 55, 43-7		1
803	Small versus large-sized drug-eluting beads (DEBIRI) for the treatment of hepatic colorectal metastases: a propensity score matching analysis. <i>CardioVascular and Interventional Radiology</i> , 2015 , 38, 361-71	2.7	32
802	Bildgesteuerte, minimalinvasive Verfahren in der Onkologie. 2015 , 10, 6-12		
801	Multimodal treatment of unresectable hepatocellular carcinoma to achieve complete response results in improved survival. 2015 , 17, 454-60		4
800	An overview of loco-regional treatments in patients and mouse models for hepatocellular carcinoma. 2015 , 10, 9		4
799	Hong Kong consensus recommendations on the management of hepatocellular carcinoma. 2015 , 4, 51-69		35
798	Systematic review of catheter-based intra-arterial therapies in hepatocellular carcinoma: state of the art and future directions. 2015 , 88, 20140564		22
797	Nonsurgical multidisciplinary approach for recurrent hepatocellular carcinoma after surgical resection. 2015 , 2, 29-38		0
796	Imaging Modalities for Assessment of Treatment Response to Nonsurgical Hepatocellular Carcinoma Therapy: Contrast-Enhanced US, CT, and MRI. 2015 , 4, 106-14		48
795	2014 KLCSSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma. 2015 , 9, 267-317		140
794	Transarterial chemoembolization: modalities, indication, and patient selection. 2015 , 62, 1187-95		163
793	Liver Tumors/Metastases (TAE/cTACE/DEB-TACE). 2015 , 238-246		
792	Veterinary interventional oncology: from concept to clinic. 2015 , 205, 198-203		9

791	Evaluation of the plasmatic and parenchymal elution kinetics of two different irinotecan-loaded drug-eluting embolics in a pig model. 2015 , 26, 746-54	17
790	Composition-property relationships for radiopaque composite materials: pre-loaded drug-eluting beads for transarterial chemoembolization. 2015 , 30, 93-103	7
789	Development of Conventional Transarterial Chemoembolization for Hepatocellular Carcinomas in Japan: Historical, Strategic, and Technical Review. 2015 , 205, 764-73	24
788	Medical management of tumor lysis syndrome, postprocedural pain, and venous thromboembolism following interventional radiology procedures. 2015 , 32, 209-16	3
787	Transarterial Chemoembolization and (90)Y Radioembolization for Hepatocellular Carcinoma: Review of Current Applications Beyond Intermediate-Stage Disease. 2015 , 205, 742-52	31
786	Systematic review comparing the safety and efficacy of conventional and drug-eluting bead transarterial chemoembolization for inoperable hepatocellular carcinoma. 2015 , 45, 190-200	60
785	Transarterial embolization therapies for the treatment of hepatocellular carcinoma: CEPO review and clinical recommendations. 2015 , 17, 52-65	17
784	Nomograms for Predicting Outcomes after Chemoembolization in Patients with Nonmetastatic Hepatocellular Carcinoma. 2015 , 26, 1093-1101.e1	3
783	PET/Computed Tomography in Evaluation of Transarterial Chemoembolization. 2015 , 10, 507-17	3
782	Intra-Arterial Therapies for Liver Masses: Data Distilled. 2015 , 53, 973-84	7
781	Histologic study of the effects of chemoembolization with preloaded doxorubicin beads in patients with hepatocellular carcinoma. 2015 , 57, 419-427	2
780	Is radioembolization ((90)Y) better than doxorubicin drug eluting beads (DEBDOX) for hepatocellular carcinoma with portal vein thrombosis? A retrospective analysis. 2015 , 24, 270-5	19
779	Histologic study of the effects of chemoembolization with preloaded doxorubicin beads in patients with hepatocellular carcinoma. 2015 , 57, 419-27	1
778	Reply: Heterogeneity of intermediate-stage HCC necessitates personalized management including surgery. 2015 , 12, 10	14
777	Managing complications in cirrhotic patients. 2015 , 3, 80-94	9
776	Clinical trials of interventional oncology-moving from efficacy to outcomes. 2015 , 12, 93-104	15
775	Clinical and economic impact of drug eluting beads in transarterial chemoembolization for hepatocellular carcinoma. 2015 , 40, 83-90	10
774	Evaluation and management of hepatocellular carcinoma. 2015 , 19, 23-43	42

773	American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. 2015 , 148, 221-244.e3		335
772	Management of hepatocellular carcinoma. 2015 , 141, 861-76		79
771	Sunitinib-eluting beads for chemoembolization: methods for in vitro evaluation of drug release. 2015 , 482, 68-74		14
770	Transarterial chemoembolization for primary liver malignancies and colorectal liver metastasis. 2015 , 24, 149-66		13
769	Drug-Eluting Beads Loaded With Doxorubicin (DEBDOX) Chemoembolisation Before Liver Transplantation for Hepatocellular Carcinoma: An Imaging/Histologic Correlation Study. <i>CardioVascular and Interventional Radiology</i> , 2015 , 38, 685-92	2.7	8
768	Transarterial chemoembolization for hepatocellular carcinoma with a new generation of beads: clinical-radiological outcomes and safety profile. <i>CardioVascular and Interventional Radiology</i> , 2015 , 38, 129-34	2.7	44
767	Conventional chemoembolization and chemoembolization with drug-eluting beads: Technique and future potential. 120-127		
766	New advances in hepatocellular carcinoma. 2016 , 8, 421-38		102
765	Angiogenesis Inhibitors for the Treatment of Hepatocellular Carcinoma. 2016 , 7, 428		48
764	Minimally invasive image-guided therapies for hepatocellular carcinoma. 2016 , 3, 55-61		8
763	Eastern Canadian Gastrointestinal Cancer Consensus Conference 2016. 2016 , 23, e605-e614		6
762	Transarterial chemoembolization with drug-eluting beads in hepatocellular carcinoma. 2016 , 22, 8853-8861		26
761	Bridging and downstaging therapy in patients suffering from hepatocellular carcinoma waiting on the list of liver transplantation. 2016 , 1, 34		14
760	Transarterial chemoembolization with drug-eluting beads versus conventional transarterial chemoembolization in locally advanced hepatocellular carcinoma. 2016 , 8, 69-74		16
759	Hepatocellular carcinoma: a review. 2016 , 3, 41-53		568
758	The Therapeutic Efficacy and Safety of Compound Kushen Injection Combined with Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma: An Update Systematic Review and Meta-Analysis. 2016 , 7, 70		39
757	National Cancer Centre Singapore Consensus Guidelines for Hepatocellular Carcinoma. 2016 , 5, 97-106		39
756	Pharmacokinetics, Safety, and Efficacy of Chemoembolization with Doxorubicin-Loaded Tightly Calibrated Small Microspheres in Patients with Hepatocellular Carcinoma. <i>CardioVascular and Interventional Radiology</i> , 2016 , 39, 1379-91	2.7	22

755	Advanced Hepatocellular Cancer: the Current State of Future Research. 2016 , 17, 43	40
754	Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data. 2016 , 64, 106-16	319
753	Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma. 2016 , 31, 645-53	55
752	Lipiodol transarterial chemoembolization for hepatocellular carcinoma: Where are we now?. 2016 , 64, 23-5	12
751	Synthesis of 24-h soluble gelatin sponge particles and their effect on liver necrosis following hepatic artery embolization: Results of in vitro and in vivo studies. 2016 , 46, 335-42	2
750	In vitro clearance of doxorubicin with a DNA-based filtration device designed for intravascular use with intra-arterial chemotherapy. 2016 , 18, 98	9
749	Optimization of an endovascular magnetic filter for maximized capture of magnetic nanoparticles. 2016 , 18, 109	6
748	Oncological management of primary liver cancer in the era of minimal access surgery. 2016 , 185-199	
747	Interventional radiology in the management of hepatopancreatobiliary malignancy and surgical complications. 2016 , 100-119	
746	C-arm computed tomography and volume perfusion computed tomography (VPCT)-based assessment of blood volume changes in hepatocellular carcinoma in prediction of midterm tumor response to transarterial chemoembolization: a single center retrospective trial. 2016 , 16, 30	9
745	Survival of patients with intermediate stage hepatocellular carcinoma treated with superselective transarterial chemoembolization using doxorubicin-loaded DC Bead under cone-beam computed tomography control. 2016 , 50, 418-426	14
744	Nine-year experience of doxorubicin-eluting beads chemoembolization for hepatocellular carcinoma. 2016 , 15, 493-498	11
743	Multifunctional microbeads for drug delivery in TACE. 2016 , 13, 1289-300	16
742	Comparison of outcomes between SBRT, yttrium-90 radioembolization, transarterial chemoembolization, and radiofrequency ablation as bridge to transplant for hepatocellular carcinoma. 2016 , 1, 35-42	49
741	Interventional oncology for hepatocellular carcinoma. 2016 , 40, 530-537	6
740	Comparative analysis of current guidelines for the treatment of hepatocellular carcinoma. 2016 , 3, 119-136	7
739	Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: A meta-analysis. 2016 , 48, 571-7	125
738	Single- versus Triple-Drug Chemoembolization for Hepatocellular Carcinoma: Comparing Outcomes by Toxicity, Imaging Response, and Survival. 2016 , 27, 1279-1287	10

737	Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality. 2016 , 10, 883-892	24
736	Management of Hepatocellular Carcinoma (HCC). 2016 , 4, 1	5
735	Hepatitis B and Hepatocellular Carcinoma. 2016 , 20, 703-720	23
734	Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH. 2016 , 146, 511.e1-511.e22	1
733	An In Vitro Evaluation of Four Types of Drug-Eluting Microspheres Loaded with Doxorubicin. 2016 , 27, 1425-1431	45
732	Efficacy and safety of cTACE versus DEB-TACE in patients with hepatocellular carcinoma: a meta-analysis. 2016 , 17, 510-517	69
731	Conventional versus Drug-Eluting Bead Transarterial Chemoembolization for Neuroendocrine Tumor Liver Metastases. 2016 , 27, 1298-1304	15
730	Treatment of hepatocellular carcinoma: beyond international guidelines. 2016 , 36 Suppl 1, 124-9	57
729	Current status and future prospects of chemotherapy for advanced hepatocellular carcinoma. 2016 , 9, 184-90	26
728	Efficacy of low dose capecitabine and sorafenib in patients with advanced alfa-fetoprotein secreting hepatocellular carcinoma: a 1 year experience. 2016 , 5, 1675	1
727	Cancer and liver cirrhosis: implications on prognosis and management. 2016 , 1, e000042	124
726	Les traitements radiologiques du carcinome hépatocellulaire: chimio-embolisation et radiofréquence percutanée. 2016 , 40, 411-415	
725	Management of neuroendocrine tumors. 2016 , 73, 1729-1744	10
724	Liver Infarction after Drug-Eluting Embolic Transarterial Chemoembolization for Hepatocellular Carcinoma in the Setting of a Large Portosystemic Shunt. 2016 , 33, 337-341	3
723	In vitro comparative study of drug loading and delivery properties of bioresorbable microspheres and LC bead. 2016 , 27, 174	4
722	Transarterial Radioembolization for Hepatocellular Carcinoma: Who, When and Y(90)? 2016 , 151, 1062-1065	0
721	Drug-eluting beads transarterial chemoembolization is feasible treatment option for advanced hepatocellular carcinoma with portal vein tumor thrombosis. 2016 , 57, 132-134	
720	Safety and effectiveness of 5-fluorouracil loaded microsphere for classical hepatocellular carcinoma. 2016 , 57, 190-192	

719	A Recent Advance in Image-Guided Locoregional Therapy for Hepatocellular Carcinoma. 2016 , 3, 90-102		12
718	Lipiodol retention pattern assessed by cone beam computed tomography during conventional transarterial chemoembolization of hepatocellular carcinoma: accuracy and correlation with response. 2016 , 16, 32		10
717	Reply: Which is the Best Chemotherapeutic Agent for Transarterial Chemoembolization of Hepatocellular Carcinoma?. <i>CardioVascular and Interventional Radiology</i> , 2016 , 39, 955-6	2.7	
716	Mechanism and Natural Course of Tumor Involution in Hepatocellular Carcinoma Following Transarterial Ethanol Ablation. <i>CardioVascular and Interventional Radiology</i> , 2016 , 39, 1136-43	2.7	3
715	Interventional Radiology for Liver Lesions. 2016 , 51, 367-377		1
714	New Approaches in Locoregional Therapies for Hepatocellular Carcinoma. 2016 , 47, 239-46		5
713	Induction Chemotherapy for Hepatocellular Carcinoma. 2016 , 269-284		
712	Drug-Eluting Bead Transarterial Chemoembolization as Bridge Therapy for Hepatocellular Carcinoma Before Living-Donor Liver Transplantation. 2016 , 48, 1045-8		16
711	Multimodality Imaging of Ethiodized Oil-loaded Radiopaque Microspheres during Transarterial Embolization of Rabbits with VX2 Liver Tumors. 2016 , 279, 741-53		17
710	Cost-effectiveness of doxorubicin-eluting beads versus conventional trans-arterial chemo-embolization for hepatocellular carcinoma. 2016 , 48, 798-805		34
709	TACE vs DEB-TACE: Who wins?. 2016 , 48, 796-7		8
708	Advances in transarterial therapies for hepatocellular carcinoma: is novel technology leading to better outcomes?. 2016 , 3, 109-118		2
707	Superselective Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma: Rationale, Technique, and Outcome. 2016 , 27, 1269-1278		37
706	Reassessing the boundaries of liver transplantation for hepatocellular carcinoma: Where do we stand with tumor down-staging?. 2016 , 63, 1014-25		97
705	Transarterial Ethanol Ablation for Unresectable Hepatocellular Carcinoma: Analysis of Clinical and Tumor Outcomes. 2016 , 27, 639-49		6
704	A bispecific protein rG7S-MICA recruits natural killer cells and enhances NKG2D-mediated immunosurveillance against hepatocellular carcinoma. 2016 , 372, 166-78		27
703	Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. 2016 , 64, 1090-1098		407
702	Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. 2016 , 150, 835-53		1012

701	Mechanisms of doxorubicin resistance in hepatocellular carcinoma. 2016 , 3, 57-59	77
700	Survival in unresectable AJCC stage I and II HCC and the effect of DEB-TACE: SEER versus tertiary cancer center cohort study. 2016 , 5, 141-54	2
699	Antitumoral Effect of Sunitinib-eluting Beads in the Rabbit VX2 Tumor Model. 2016 , 280, 425-35	24
698	Hepatocellular carcinoma: From diagnosis to treatment. 2016 , 25, 74-85	248
697	Correlation of Doxorubicin Delivery and Tumor Necrosis after Drug-eluting Bead Transarterial Chemoembolization of Rabbit VX2 Liver Tumors. 2016 , 280, 752-61	27
696	Sociodemographic impact on survival in unresectable hepatocellular carcinoma: a survival epidemiology and end results study. 2016 , 12, 183-98	8
695	Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone. 2016 , 34, 2046-53	239
694	Preparation of Radiopaque Drug-Eluting Beads for Transcatheter Chemoembolization. 2016 , 27, 117-126.e3	17
693	Advances in Local and Systemic Therapies for Hepatocellular Cancer. 2016 , 18, 9	13
692	Transarterial Therapies for Hepatocellular Carcinoma. 2016 , 51, 95-105	4
691	In vitro and in vivo evaluation of drug-eluting microspheres designed for transarterial chemoembolization therapy. 2016 , 503, 150-62	17
690	[Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH]. 2016 , 146, 511.e1-511.e22	36
689	Conventional Ethiodized Oil Transarterial Chemoembolization for Treatment of Hepatocellular Carcinoma: Contemporary Single-Center Review of Clinical Outcomes. 2016 , 206, 645-54	13
688	Polymeric materials for embolic and chemoembolic applications. 2016 , 240, 414-433	62
687	TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON. 2016 , 279, 630-40	85
686	Hepatocellular Carcinoma Post Embolotherapy: Imaging Appearances and Pitfalls on Computed Tomography and Magnetic Resonance Imaging. 2016 , 67, 158-72	12
685	ACR Appropriateness Criteria Radiologic Management of Hepatic Malignancy. 2016 , 13, 265-73	7
684	Arming embolic beads with anti-VEGF antibodies and controlling their release using LbL technology. 2016 , 224, 199-207	25

683	DC BeadM1ϭtowards an optimal transcatheter hepatic tumour therapy. 2016 , 27, 13		26
682	In Vitro Capture of Small Ferrous Particles with a Magnetic Filtration Device Designed for Intravascular Use with Intraarterial Chemotherapy: Proof-of-Concept Study. 2016 , 27, 426-32.e1		8
681	Reactivation of Hepatitis B Virus Due to Cancer Chemotherapy and Other Immunosuppressive Drug Therapy. 2016 , 399-431		
680	Treatment of Liver Tumors with Lipiodol TACE: Technical Recommendations from Experts Opinion. <i>CardioVascular and Interventional Radiology</i> , 2016 , 39, 334-43	2.7	133
679	Superselective Chemoembolization of HCC: Comparison of Short-term Safety and Efficacy between Drug-eluting LC Beads, QuadraSpheres, and Conventional Ethiodized Oil Emulsion. 2016 , 278, 612-21		28
678	Cone Beam Computed Tomography (CBCT) in the Field of Interventional Oncology of the Liver. <i>CardioVascular and Interventional Radiology</i> , 2016 , 39, 8-20	2.7	49
677	In Vivo Proof of Superselective Transarterial Chemoembolization with 40-ϭ Drug-Eluting Beads in a Patient with Hepatocellular Carcinoma. <i>CardioVascular and Interventional Radiology</i> , 2016 , 39, 137-40	2.7	2
676	Predictive factors for complete response of chemoembolization with drug-eluting beads (DEB-TACE) for hepatocellular carcinoma. 2016 , 26, 1640-8		50
675	Evaluation of drug-eluting beads versus conventional transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma: A systematic review and meta-analysis. 2017 , 41, 75-85		34
674	Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization. 2017 , 27, 526-535		39
673	Hepatic arterial damage after transarterial chemoembolization for the treatment of hepatocellular carcinoma: comparison of drug-eluting bead and conventional chemoembolization in a retrospective controlled study. 2017 , 58, 131-139		24
672	Clinical features and prognosis of elderly patients with hepatocellular carcinoma not indicated for surgical resection. 2017 , 17, 189-201		18
671	Should we routinely use DEBTACE for unresectable HCC? cTACE versus DEBTACE: a single-center survival analysis. 2017 , 69, 67-73		14
670	Non-transplant therapies for patients with hepatocellular carcinoma and Child-Pugh-Turcotte class B cirrhosis. 2017 , 18, e101-e112		87
669	[Liver metastases of colorectal cancer]. 2017 , 57, 90-96		4
668	Validation of the Risk Prediction Models STATE-Score and START-Strategy to Guide TACE Treatment in Patients with Hepatocellular Carcinoma. <i>CardioVascular and Interventional Radiology</i> , 2017 , 40, 1017-1025	2.7	14
667	Safety and efficacy of HepaSphere 50-100 ϭ in the treatment of hepatocellular carcinoma. 2017 , 26, 212-219		3
666	Liver blood flow. 2017 , 77-92.e5		

665	Neutrophil to lymphocyte ratio predicts disease progression following intra-arterial therapy of hepatocellular carcinoma. 2017 , 19, 458-464	22
664	Review of the Development of Methods for Characterization of Microspheres for Use in Embolotherapy: Translating Bench to Cathlab. 2017 , 6, 1601291	30
663	Bridging locoregional therapy: Longitudinal trends and outcomes in patients with hepatocellular carcinoma. 2017 , 31, 136-143	6
662	Management of people with intermediate-stage hepatocellular carcinoma: an attempted network meta-analysis. 2017 , 3, CD011649	13
661	Loco-regional treatment of HCC: current status. 2017 , 72, 626-635	50
660	Early response evaluation using CT-perfusion one day after transarterial chemoembolization for HCC predicts treatment response and long-term disease control. 2017 , 90, 73-80	17
659	DEB TACE for Intermediate and advanced HCC - Initial Experience in a Brazilian Cancer Center. 2017 , 17, 5	10
658	Characterization of a novel intrinsically radiopaque Drug-eluting Bead for image-guided therapy: DC Bead LUMI. 2017 , 250, 36-47	46
657	Unusual behaviour induced by phase separation in hydrogel microspheres. 2017 , 53, 190-198	4
656	Overexpression of NAD(P)H: Quinone Oxidoreductase 1 Inhibits Hepatocellular Carcinoma Cell Proliferation and Induced Apoptosis by Activating AMPK/PGC-1 β Pathway. 2017 , 36, 256-263	12
655	Radiofrequency vs Microwave Ablation After Neoadjuvant Transarterial Bland and Drug-Eluting Microsphere Chemolization for the Treatment of Hepatocellular Carcinoma. 2017 , 46, 402-409	15
654	Update on Embolization Therapies for Hepatocellular Carcinoma. 2017 , 19, 40	23
653	Tumor Enhancement and Heterogeneity Are Associated With Treatment Response to Drug-Eluting Bead Chemoembolization for Hepatocellular Carcinoma. 2017 , 41, 289-293	15
652	Safety and efficacy of doxorubicin-eluting superabsorbent polymer microspheres for the treatment of liver metastases from neuroendocrine tumours: preliminary results. 2017 , 51, 74-80	6
651	Poly(acrylic acid) microspheres loaded with superparamagnetic iron oxide nanoparticles for transcatheter arterial embolization and MRI detectability: In vitro and in vivo evaluation. 2017 , 527, 31-41	10
650	Segmental Yttrium-90 Radioembolization versus Segmental Chemoembolization for Localized Hepatocellular Carcinoma: Results of a Single-Center, Retrospective, Propensity Score-Matched Study. 2017 , 28, 777-785.e1	46
649	Review article: delivering precision oncology in intermediate-stage liver cancer. 2017 , 45, 1514-1523	19
648	Predictors of therapeutic effect of transarterial chemoembolisation using drug-eluting beads for hepatocellular carcinoma. 2017 , 72, 780-785	5

647	Other non-surgical treatments for liver cancer. 2017 , 22, 181-192	8
646	Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. 2017 , 11, 317-370	955
645	Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. 2017 , 2, 565-575	226
644	Risk of acute kidney injury after transarterial chemoembolisation in hepatocellular carcinoma patients: A nationwide population-based cohort study. 2017 , 27, 4482-4489	8
643	Selective targeted delivery of doxorubicin via conjugating to anti-CD24 antibody results in enhanced antitumor potency for hepatocellular carcinoma both in vitro and in vivo. 2017 , 143, 1929-1940	11
642	Anti-angiogenics in Hepatocellular Cancer Therapy. 2017 , 1-12	
641	Doxorubicin Drug-Eluting Embolic Chemoembolization of Hepatocellular Carcinoma: Study of Midterm Doxorubicin Delivery in Resected Liver Specimens. 2017 , 28, 804-810	6
640	Hypoxia as a target for drug combination therapy of liver cancer. 2017 , 28, 771-780	22
639	Chemoembolization Adopting Polyethylene Glycol Drug-Eluting Embolics Loaded With Doxorubicin for the Treatment of Hepatocellular Carcinoma. 2017 , 209, 430-434	15
638	NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017. 2017 , 15, 563-573	207
637	Transarterial Chemoembolization and Radioembolization across Barcelona Clinic Liver Cancer Stages. 2017 , 34, 109-115	8
636	Metastatic Liver Disease: Indications for Locoregional Therapy and Supporting Data. 2017 , 34, 145-166	12
635	Liver-Directed Therapy for Hepatocellular Carcinoma: An Overview of Techniques, Outcomes, and Posttreatment Imaging Findings. 2017 , 209, 67-76	22
634	Treatment Options in Patients Awaiting Liver Transplantation with Hepatocellular Carcinoma and Cholangiocarcinoma. 2017 , 21, 231-251	3
633	New concepts in embolotherapy of HCC. 2017 , 34, 58	42
632	The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy. 2017 , 67, 173-183	106
631	New Interventional Treatment Model for Pancreatic Neoplasms Using Gemcitabine-Eluting Hydrogel Devices: In Vitro and In Vivo Results. <i>CardioVascular and Interventional Radiology</i> , 2017 , 40, 1246-1254	2.7 1
630	In Vivo Drug Delivery Performance of Lipiodol-Based Emulsion or Drug-Eluting Beads in Patients with Hepatocellular Carcinoma. 2017 , 14, 448-458	20

629	Intraarterial Therapy Using Micellar Nanoparticles Incorporating SN-38 in a Rabbit Liver Tumor Model. 2017 , 28, 457-464	2
628	The diagnosis and treatment of hepatocellular carcinoma. 2017 , 34, 153-159	278
627	Korean Multicenter Registry of Transcatheter Arterial Chemoembolization with Drug-Eluting Embolic Agents for Nodular Hepatocellular Carcinomas: Six-Month Outcome Analysis. 2017 , 28, 502-512	20
626	Cancer-directed therapy and potential impact on survivals in nonresected hepatocellular carcinoma: SEER-Medicare population study. 2017 , 13, 2021-2033	4
625	Local Arterial Therapies in the Management of Unresectable Hepatocellular Carcinoma. 2017 , 18, 67	1
624	Transarterial Chemoembolization with Small Drug-Eluting Beads in Patients with Hepatocellular Carcinoma: Experience from a Cohort of 421 Patients at an Italian Center. 2017 , 28, 1495-1502	30
623	Cost-effectiveness analysis of transcatheter arterial chemoembolization with or without sorafenib for the treatment of unresectable hepatocellular carcinoma. 2017 , 16, 493-498	6
622	Liver-Directed Therapies for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. 2017 , 24, 1073274817729244	18
621	In vitro evaluation of sunitinib loaded bioresorbable microspheres for potential application in arterial chemoembolization. 2017 , 159, 705-711	1
620	Contact lenses for ophthalmic drug delivery. 2017 , 100, 494-512	34
619	Single-Center Comparison of Overall Survival and Toxicities in Patients with Infiltrative Hepatocellular Carcinoma Treated with Yttrium-90 Radioembolization or Drug-Eluting Embolic Transarterial Chemoembolization. 2017 , 28, 1371-1377	12
618	Comparison of Triple-Drug Transcatheter Arterial Chemoembolization (TACE) With Single-Drug TACE Using Doxorubicin-Eluting Beads: Long-Term Survival in 313 Patients. 2017 , 209, 722-732	19
617	Drug-eluting embolic microspheres for local drug delivery - State of the art. 2017 , 262, 127-138	39
616	Principles of Intra-Arterial Therapies. 2017 , 69-75	
615	Current guidelines for chemoembolization for hepatocellular carcinoma: Room for improvement?. 2017 , 1, 338-346	9
614	Health-related quality of life during trans-arterial chemoembolization with drug-eluting beads loaded with doxorubicin (DEBDOX) for unresectable hepatic metastases from ocular melanoma. 2017 , 214, 884-890	3
613	Bridging to liver transplantation in HCC patients. 2017 , 402, 863-871	21
612	Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres. 2017 , 71, e12972	28

611	Hepatocellular Carcinoma: Epidemiology, Basic Principles of Treatment, and Clinical Data. 2017 , 149-178		
610	Treatment of hepatocellular carcinoma using transarterial chemoembolization: a real-life, single-centre study from Southern Brazil. 2017 , 29, 225-230		1
609	An Update on Randomized Clinical Trials in Hepatocellular Carcinoma. 2017 , 26, 647-666		4
608	Safety and Efficacy of Transarterial Radioembolisation in Patients with Intermediate or Advanced Stage Hepatocellular Carcinoma Refractory to Chemoembolisation. <i>CardioVascular and Interventional Radiology</i> , 2017 , 40, 1882-1890	2.7	13
607	Intra-arterial therapy of neuroendocrine tumour liver metastases: comparing conventional TACE, drug-eluting beads TACE and yttrium-90 radioembolisation as treatment options using a propensity score analysis model. 2017 , 27, 4995-5005		34
606	Traitements intra-arteriels des carcinomes hépatocellulaires : évidence clinique et perspectives à venir. 2017 , 19, 158-167		
605	Hepatocellular carcinoma: Therapeutic strategy in 2017. 2017 , 19, 177-183		
604	Quality Improvement Guidelines for Transarterial Chemoembolization and Embolization of Hepatic Malignancy. 2017 , 28, 1210-1223.e3		69
603	Risks factors for severe pain after selective liver transarterial chemoembolization. 2017 , 37, 583-591		10
602	Conventional versus drug-eluting beads chemoembolization for hepatocellular carcinoma: Emphasis on the impact of tumor size. 2017 , 32, 487-496		24
601	Validation of Clinical Scoring Systems ART and ABCR after Transarterial Chemoembolization of Hepatocellular Carcinoma. 2017 , 28, 94-102		23
600	Liver and biliary damages following transarterial chemoembolization of hepatocellular carcinoma: comparison between drug-eluting beads and lipiodol emulsion. 2017 , 27, 1431-1439		57
599	Short-term efficacy of transarterial chemoembolization with epirubicin-loaded superabsorbent polymer microspheres for hepatocellular carcinoma: comparison with conventional transarterial chemoembolization. 2017 , 42, 612-619		7
598	Hepatocellular Carcinoma. 2017 , 977-988		
597	Role of diffusion-weighted magnetic resonance imaging in the evaluation of hepatocellular carcinoma response to transcatheter arterial chemoembolization using drug eluting beads; correlation with dynamic MRI. 2017 , 48, 817-824		3
596	Computed Tomographic Perfusion Imaging for the Prediction of Response and Survival to Transarterial Chemoembolization of Hepatocellular Carcinoma. 2018 , 52, 14-22		3
595	Sustained multiple organ ischaemia after transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. 2018 , 15, 1479-1483		6
594	Management of Hepatocellular Carcinoma in the Setting of Liver Cirrhosis. 2017 ,		

593	Hepatic artery embolization and chemoembolization of liver tumors. 2017 , 1398-1416.e4	
592	Radioembolization treatment for liver metastases. 2017 , 21, 274-278	2
591	Complete Remission after Sequential Therapy of Drug Eluting Beads Transarterial Chemoembolization and Liver Resection in Large Solitary Nodule Hepatocellular Carcinoma. 2017 , 2017, 3682614	2
590	Vandetanib-eluting Radiopaque Beads: Pharmacokinetics, Safety and Toxicity Evaluation following Swine Liver Embolization. 2017 , 7, 2164-2176	13
589	The drug delivery system used in interventional radiology. 2017 , 32, 17-28	
588	Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trials. 2017 , 12, e0184597	59
587	Hepatocellular Carcinoma: Diagnosis, Treatment Algorithms, and Imaging Appearance after Transarterial Chemoembolization. 2018 , 6, 175-188	10
586	Dual-balloon infusion microcatheter for selective drug-eluting bead transarterial chemoembolization: initial feasibility study. 2017 , 23, 454-460	8
585	Does neoadjuvant doxorubicin drug-eluting bead transarterial chemoembolization improve survival in patients undergoing liver transplant for hepatocellular carcinoma?. 2017 , 23, 441-447	5
584	Locoregional and systemic therapy for hepatocellular carcinoma. 2017 , 8, 215-228	46
583	Transarterial chemoembolization (TACE) with degradable starch microspheres (DSM) in hepatocellular carcinoma (HCC): multi-center results on safety and efficacy. 2017 , 8, 72613-72620	18
582	Medical Management of Hepatocellular Carcinoma. 2017 , 13, 356-364	27
581	Chemoembolization of liver cancer with drug-loading microsphere 50-100 μ m. 2017 , 8, 5392-5399	9
580	Conventional drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma. 2017 , 9, 808-814	56
579	Systemic therapy for advanced hepatocellular carcinoma: an update. 2017 , 8, 243-255	45
578	Downstaging for hepatocellular cancer: harm or benefit?. 2017 , 2, 106	17
577	Outpatient Transarterial Chemoembolization of Hepatocellular Carcinoma: Review of a Same-Day Discharge Strategy. 2018 , 29, 550-555	10
576	Hong Kong Consensus Statements for the Management of Unresectable Hepatocellular Carcinoma. 2018 , 7, 40-54	16

575	Challenges in chemotherapy delivery: comparison of standard chemotherapy delivery to locoregional vascular mass fluid transfer. 2018 , 14, 647-663	13
574	Transarterial chemoembolization (TACE) in the management of hepatocellular carcinoma: Results of a French national survey on current practices. 2018 , 99, 527-535	13
573	EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. 2018 , 69, 182-236	3196
572	Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. 2018 , 68, 723-750	1650
571	Evaluation of Hepatocellular Carcinoma Transarterial Chemoembolization using Quantitative Analysis of 2D and 3D Real-time Contrast Enhanced Ultrasound. 2018 , 4, 035039	14
570	Liver Cancers. 2018 , 100-116	
569	Intra-arterial idarubicin_lipiodol without embolisation in hepatocellular carcinoma: The LIDA-B phase I trial. 2018 , 68, 1163-1171	6
568	Transvascular therapy of Hepatocellular Carcinoma (HCC), status and developments. 2018 , 27, 69-80	10
567	Ablative Chemoembolization for Hepatocellular Carcinoma: A Prospective Phase I Case-Control Comparison with Conventional Chemoembolization. 2018 , 287, 340-348	4
566	Hepatocellular carcinoma treatment: ablation and arterial embolization. 2018 , 60, 156-166	1
565	Liver-directed therapy for hepatocellular carcinoma. 2018 , 43, 203-217	8
564	Locoregional Therapies for Hepatocellular Carcinoma. 2018 , 213-233	
563	Hepatocellular carcinoma. 2018 , 391, 1301-1314	2402
562	Chemoembolization of Hepatocellular Carcinoma with Drug-Eluting Polyethylene Glycol Embolic Agents: Single-Center Retrospective Analysis in 302 Patients. 2018 , 29, 841-849	12
561	A randomized placebo-controlled trial of prophylactic dexamethasone for transcatheter arterial chemoembolization. 2018 , 67, 575-585	32
560	Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. 2018 , 117, 381-403	58
559	Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. 2018 , 3, 37-46	69
558	Therapies for advanced stage hepatocellular carcinoma with macrovascular invasion or metastatic disease: A systematic review and meta-analysis. 2018 , 67, 422-435	125

557	Hemobilia immediately after transcatheter arterial chemoembolization using drug-eluting beads for hepatocellular carcinoma with intrahepatic bile duct invasion. 2018 , 48, 329-332		3
556	Safety and Feasibility of Chemoembolization with Doxorubicin-Loaded Small Calibrated Microspheres in Patients with Hepatocellular Carcinoma: Results of the MIRACLE I Prospective Multicenter Study. <i>CardioVascular and Interventional Radiology</i> , 2018 , 41, 587-593	2.7	27
555	Liver transplantation beyond or downstaging within the Milan criteria for hepatocellular carcinoma. 2018 , 12, 265-275		13
554	Reply to "Comment on 'In Vivo Drug Delivery Performance of Lipiodol-Based Emulsion or Drug-Eluting Beads in Patients with Hepatocellular Carcinoma'". 2018 , 15, 336-340		1
553	Newly developed triaxial microcatheter for complicated interventions. 2018 , 27, 11-16		5
552	Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma. 2018 , 67, 380-388		95
551	Intraprocedural 3D perfusion measurement during chemoembolisation with doxorubicin-eluting beads in liver metastases of malignant melanoma. 2018 , 28, 1456-1464		5
550	Efficacy and safety of transarterial chemoembolization with 70- to 150- μ m drug-eluting beads alone or in combination with 100- to 300- μ m drug-eluting beads. 2018 , 31, 428-431		1
549	Stereotactic body radiation therapy following transarterial chemoembolization for unresectable hepatocellular carcinoma. 2018 , 9, 734-740		14
548	Drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma: Current state of the art. 2018 , 24, 161-169		63
547	Vascular lakes after doxorubicin drug-eluting bead chemoembolization with histologic analysis. 2018 , 31, 541-542		
546	Comprehensive analysis of common safety profiles and their predictive factors in 520 records of liver cancer patients treated by drug-eluting beads transarterial chemoembolization. 2018 , 97, e11131		6
545	Rash and subcutaneous fat necrosis after DEB-TACE with doxorubicin. 2018 , 2018,		3
544	HCC in Elderly Patients. Curative Intraoperative Strategies and Management in Recurrences. 2018 ,		0
543	Non-Contrast Perfusion Ultrasound Imaging for Assessment of Trans-Arterial Chemoembolization for Hepatic Malignancy. 2018 ,		
542	Treatment of Primary Liver Tumors and Liver Metastases, Part 2: Non-Nuclear Medicine Techniques. 2018 , 59, 1801-1808		7
541	Complications of Transarterial Chemoembolization (TACE) in the Treatment of Liver Tumors. 2018 , 96, 560-567		4
540	Complications of transarterial chemoembolization (TACE) in the treatment of liver tumors. 2018 , 96, 560-567		16

539	Transcatheter arterial chemoembolization combined with radiofrequency or microwave ablation for hepatocellular carcinoma: a review. 2018 , 5, HEP07	10
538	Post Locoregional Therapy Treatment Imaging in Hepatocellular Carcinoma Patients: A Literature-based Review. 2018 , 6, 189-197	14
537	Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2018 , 29, iv238-iv255	355
536	The integration of pharmacology and pathophysiology into locoregional chemotherapy delivery via mass fluid transfer. 2018 , 292, 18-28	1
535	Indications and Best Practices for Intra-arterial Therapies to Treat Hepatocellular Carcinoma. 2018 , 17, 399-411	
534	Acute necrotizing pancreatitis as a fatal complication following DC Bead transcatheter arterial chemoembolization for hepatocellular carcinoma: A case report and review of the literature. 2018 , 9, 403-407	2
533	Analysis of survival and prognostic factors in treatment of hepatocellular carcinoma in Spanish patients with drug-eluting bead transarterial chemoembolization. 2018 , 30, 1453-1460	1
532	Effect of PAK1 gene silencing on proliferation and apoptosis in hepatocellular carcinoma cell lines MHCC97-H and HepG2 and cells in xenograft tumor. 2018 , 25, 284-296	14
531	Transarterial Chemoembolization for Hepatocellular Carcinoma. 2018 , 37, 107-111	4
530	Comprehensive Analysis of Factors Affecting Clinical Response and Short-Term Survival to Drug-Eluting Bead Transarterial Chemoembolization for Treatment in Patients With Liver Cancer. 2018 , 17, 1533033818759878	6
529	Intraprocedural Parenchymal Blood Volume Is a Predictor of Treatment Response for Chemoembolization in Hepatocellular Carcinoma: Results of a Prospective Study. 2018 , 29, 928-935	3
528	Bench-to-clinic development of imageable drug-eluting embolization beads: finding the balance. 2018 , 14, 2741-2760	17
527	Liver chemoembolization of hepatocellular carcinoma using TANDEM microspheres. 2018 , 14, 2761-2772	8
526	Repeated Transarterial Chemoembolization with Degradable Starch ?Microspheres (DSMs-TACE) of Unresectable Hepatocellular Carcinoma: A Prospective Pilot Study. 2018 , 14, 637-645	7
525	Efficacy and safety profile of drug-eluting beads transarterial chemoembolization by CalliSpheres® beads in Chinese hepatocellular carcinoma patients. 2018 , 18, 644	35
524	Comparison of Stable and Unstable Ethiodized Oil Emulsions for Transarterial Chemoembolization of Hepatocellular Carcinoma: Results of a Single-Center Double-Blind Prospective Randomized Controlled Trial. 2018 , 29, 1068-1077.e2	8
523	DEB-TACE: a standard review. 2018 , 14, 2969-2984	38
522	Validation of the SNACOR clinical scoring system after transarterial chemoembolisation in patients with hepatocellular carcinoma. 2018 , 18, 489	10

521	CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study. 2018 , 16, 69			51
520	Embolization Materials, Catheters, and Intra-Arterial Ports. 2018 , 21-39			
519	Mapping Drug Dose Distribution on CT Images Following Transarterial Chemoembolization with Radiopaque Drug-Eluting Beads in a Rabbit Tumor Model. 2018 , 289, 396-404			21
518	Multidisciplinary Taiwan Consensus Recommendations for the Use of DEBDOX-TACE in Hepatocellular Carcinoma Treatment. 2018 , 7, 312-322			4
517	MT1G is Silenced by DNA Methylation and Contributes to the Pathogenesis of Hepatocellular Carcinoma. 2018 , 9, 2807-2816			11
516	PD-1 Blockade for Improving the Antitumor Efficiency of Polymer-Doxorubicin Nanoprodrug. 2018 , 14, e1802403			42
515	Transarterial Chemoembolization. 2018 , 381-387			1
514	HCC. 2018 , 43-82			
513	Transarterial Radioembolization Following Chemoembolization for Unresectable Hepatocellular Carcinoma: Response Based on Apparent Diffusion Coefficient Change is an Independent Predictor for Survival. <i>CardioVascular and Interventional Radiology</i> , 2018 , 41, 1716-1726	2.7		4
512	Primary Malignant Neoplasms of the Liver. 2018 , 705-729			1
511	Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition). 2018 , 7, 235-260			291
510	Reactivation of intraabdominal tuberculous lymphadenopathy after drug-eluting beads transcatheter arterial chemoembolization in a patient with hepatocellular carcinoma. 2019 , 12, 76-81			4
509	CalliSpheres® drug-eluting beads (DEB) transarterial chemoembolization (TACE) is equally efficient and safe in liver cancer patients with different times of previous conventional TACE treatments: a result from CTILC study. 2019 , 21, 167-177			24
508	Effectiveness of drug-eluting bead transarterial chemoembolization versus conventional transarterial chemoembolization for small hepatocellular carcinoma in Child-Pugh class A patients. 2019 , 11, 1758835919866072			6
507	Current State of Liver-Directed Therapies and Combinatory Approaches with Systemic Therapy in Hepatocellular Carcinoma (HCC). 2019 , 11,			27
506	Interventional Radiologic Therapies for Hepatocellular Carcinoma: From Where We Began to Where We Are Going. 2019 , 169-194			1
505	Transarterial Chemoembolization of Hepatocellular Carcinoma with Idarubicin-Loaded Tandem Drug-Eluting Embolics. 2019 , 11,			8
504	Contrasting Some Differences in Managing Advanced Unresectable Hepatocellular Carcinoma Between the East and the West. 2019 , 31, 560-569			2

503	Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting. 2019 , 54, 905-912		10
502	Correlation between SACE (Subjective Angiographic Chemoembolization Endpoint) score and tumor response and its impact on survival after DEB-TACE in patients with hepatocellular carcinoma. 2019 , 44, 3463-3479		3
501	Safety and Prognosis of Transarterial Chemoembolization for Octogenarians with Hepatocellular Carcinoma. <i>CardioVascular and Interventional Radiology</i> , 2019 , 42, 1413-1419	2.7	8
500	Treatment of Hepatocellular Carcinoma: Time for a Paradigm Shift?. 2019 , 292, 760-761		1
499	Minimally invasive gas embolization using acoustic droplet vaporization in a rodent model of hepatocellular carcinoma. 2019 , 9, 11040		7
498	Treatment Lines in Hepatocellular Carcinoma. 2019 , 35, 266-272		17
497	Prospective Phase II trial of drug-eluting bead chemoembolization for liver transplant candidates with hepatocellular carcinoma and marginal hepatic reserve. 2019 , 6, 93-103		6
496	The clinical safety and efficacy of conventional transcatheter arterial chemoembolization and drug-eluting beads-transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A meta-analysis. 2019 , 13, 374-381		9
495	Survival, tumour response and safety of 70-150 μ m versus 100-300 μ m doxorubicin drug-eluting beads in transarterial chemoembolisation for hepatocellular carcinoma. 2019 , 63, 802-811		11
494	Neutrophil/Lymphocyte Ratio Predicts Increased Risk of Immediate Progressive Disease following Chemoembolization of Hepatocellular Carcinoma. 2019 , 30, 1887-1892		13
493	Early Experience of Trans-arterial Chemo-Embolicisation for Hepatocellular Carcinoma with a Novel Radiopaque Bead. <i>CardioVascular and Interventional Radiology</i> , 2019 , 42, 1563-1570	2.7	7
492	MRI assessment of hepatocellular carcinoma after locoregional therapy. 2019 , 10, 8		14
491	Evaluation of novel formulations for transarterial chemoembolization: combining elements of Lipiodol emulsions with Drug-eluting Beads. 2019 , 9, 5626-5641		7
490	Loco-regional intervention for hepatocellular carcinoma. 2019 , 2, 43-46		
489	Transarterial chemoembolization with pirarubicin-eluting microspheres in patients with unresectable hepatocellular carcinoma: Preliminary results. 2019 , 2, 69-77		1
488	Non-contrast power Doppler ultrasound imaging for early assessment of trans-arterial chemoembolization of liver tumors. 2019 , 9, 13020		2
487	Polyethylene Glycol Epirubicin-Loaded Transcatheter Arterial Chemoembolization Procedures Utilizing a Combined Approach with 100 and 200 μ m Microspheres: A Promising Alternative to Current Standards. 2019 , 30, 305-313		8
486	Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study. 2019 , 70, 893-903		81

485	Chemoembolization of HCC: Time for Technical Standardization, or Is It Too Late?. <i>CardioVascular and Interventional Radiology</i> , 2019 , 42, 1329-1330	2.7
484	Yttrium-90 trans-arterial radioembolization in advanced-stage HCC: The impact of portal vein thrombosis on survival. 2019 , 14, e0216935	14
483	Predicting pharmacokinetic behaviour of drug release from drug-eluting embolization beads using in vitro elution methods. 2019 , 136, 104943	14
482	An In Vitro Evaluation of Four Types of Drug-Eluting Embolics Loaded with Idarubicin. 2019 , 30, 1303-1309	4
481	Advances in Biomaterials and Technologies for Vascular Embolization. 2019 , 31, e1901071	59
480	Theranostics in Interventional Oncology: Versatile Carriers for Diagnosis and Targeted Image-Guided Minimally Invasive Procedures. 2019 , 10, 450	15
479	Bridging Hepatocellular Carcinoma to Transplant: Transarterial Chemoembolization Response, Tumor Biology, and Recurrence after Transplantation in a 12-Year Transplant Cohort. 2019 , 30, 995-1003	4
478	Comparison of Treatment Response and Survival Profiles Between Drug-Eluting Bead Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Chinese Hepatocellular Carcinoma Patients: A Prospective Cohort Study. 2019 , 27, 583-592	5
477	Diffusion-weighted imaging of hepatocellular carcinoma before and after transarterial chemoembolization: role in survival prediction and response evaluation. 2019 , 44, 2740-2750	7
476	Clinical Pharmacokinetics and Pharmacodynamics of Transarterial Chemoembolization and Targeted Therapies in Hepatocellular Carcinoma. 2019 , 58, 983-1014	13
475	Imaging biomarkers for well and moderate hepatocellular carcinoma: preoperative magnetic resonance image and histopathological correlation. 2019 , 19, 364	7
474	Using principal component analysis for the prediction of tumor response to transarterial chemoembolization. 2019 , 44, 2594-2601	1
473	Change in Perfusion Angiography During Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Predicts Short-Term Outcomes. 2019 , 213, 746-754	3
472	Risk factors for local recurrence of hepatocellular carcinoma after transcatheter arterial chemoembolization with drug-eluting beads (DEB-TACE). 2019 , 37, 543-548	5
471	Idarubicin-loaded Beads for Chemoembolization of Hepatocellular Carcinoma: The IDASPHERE II Single-Arm Phase II Trial. 2019 , 291, 801-808	11
470	Long-term follow-up after conventional transarterial chemoembolization (c-TACE) with mitomycin for hepatocellular carcinoma (HCC). 2019 , 10, 348-353	5
469	HCC: Transarterial Therapies-What the Interventional Radiologist Can Offer. 2019 , 64, 959-967	9
468	ROR1 Expression and Its Functional Significance in Hepatocellular Carcinoma Cells. 2019 , 8,	7

467	Safety and efficacy assessment of transarterial chemoembolization using drug-eluting beads in patients with hepatocellular carcinoma and arterioportal shunt: a single-center experience. 2019 , 11, 1551-1557		11
466	Balloon-Occluded Transcatheter Arterial Chemoembolization (b-TACE) for Hepatocellular Carcinoma Performed with Polyethylene-Glycol Epirubicin-Loaded Drug-Eluting Embolics: Safety and Preliminary Results. <i>CardioVascular and Interventional Radiology</i> , 2019 , 42, 853-862	2.7	17
465	Locoregional Therapy, Immunotherapy and the Combination in Hepatocellular Carcinoma: Future Directions. 2019 , 8, 326-340		19
464	Combining Slow Flow Techniques With Adaptive Demodulation for Improved Perfusion Ultrasound Imaging Without Contrast. 2019 , 66, 834-848		7
463	Better survival after stereotactic body radiation therapy following transarterial chemoembolization in nonresectable hepatocellular carcinoma: A propensity score matched analysis. 2019 , 28, 228-235		14
462	Does Drug-Eluting Bead TACE Enhance the Local Effect of IRE? Imaging and Histopathological Evaluation in a Porcine Model. <i>CardioVascular and Interventional Radiology</i> , 2019 , 42, 880-885	2.7	4
461	Hepatocellular Carcinoma: Treatment. 2019 , 703-714		
460	Synthesis and assessment of drug-eluting microspheres for transcatheter arterial chemoembolization. 2019 , 88, 370-382		8
459	Liver Directed Therapies. 2019 ,		
458	Regional Chemotherapy for Biliary Tract Tumors and Hepatocellular Carcinoma. 2019 , 28, 717-729		4
457	Role of Radioembolization for Biliary Tract and Primary Liver Cancer. 2019 , 28, 731-743		5
456	Update on transarterial approaches to locoregional treatment in hepatocellular carcinoma. 2019 , 31, 339-345		3
455	Conventional versus drug-eluting beads chemoembolization for infiltrative hepatocellular carcinoma: a comparison of efficacy and safety. 2019 , 19, 1162		11
454	Drug-eluting bead transarterial chemoembolization (TACE) vs conventional TACE in treating hepatocellular carcinoma patients with multiple conventional TACE treatments history: A comparison of efficacy and safety. 2019 , 98, e15314		19
453	ALBI and P-ALBI grade in Child-Pugh A patients treated with drug eluting embolic chemoembolization for hepatocellular carcinoma. 2019 , 60, 702-709		8
452	Safety and Effectiveness of Suture-mediated Arterial Closure Device in Hepatocellular Carcinoma Patients Who Underwent Drug-Eluting Beads Transarterial Chemoembolization. 2019 , 55, 203-209		
451	Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. 2019 , 72, 28-36		163
450	A review discussing the use of polyethylene glycol microspheres in the treatment of hepatocellular carcinoma. 2019 , 15, 695-703		4

449	Therapeutic advances for patients with intermediate hepatocellular carcinoma. 2019 , 234, 12116-12121		20
448	Time-to-progression following conventional compared with drug-eluting-bead transcatheter arterial chemoembolisation in patients with large hepatocellular carcinoma. 2019 , 74, 295-300		4
447	Huge Hepatocellular Carcinoma Treated with Radical Hepatectomy after Drug-eluting Bead Transarterial Chemoembolization. 2019 , 58, 1103-1110		2
446	Update on Transarterial Chemoembolization with Drug-Eluting Microspheres for Hepatocellular Carcinoma. 2019 , 20, 34-49		27
445	Current trends in the treatment of hepatocellular carcinoma with transarterial embolization: a cross-sectional survey of techniques. 2019 , 29, 3287-3295		21
444	Role of liver and spleen stiffness in predicting the recurrence of hepatocellular carcinoma after resection. 2019 , 70, 440-448		58
443	Recent advances in medical management of hepatocellular carcinoma. 2019 , 49, 14-32		41
442	Comparison of health-related quality of life after transarterial chemoembolization and transarterial radioembolization in patients with unresectable hepatocellular carcinoma. 2019 , 44, 1554-1561		13
441	Regional therapies for the treatment of primary and metastatic hepatic tumors: A disease-based review of techniques and critical appraisal of current evidence. 2019 , 217, 541-545		5
440	Radioablation by Image-Guided (HDR) Brachytherapy and Transarterial Chemoembolization in Hepatocellular Carcinoma: A Randomized Phase II Trial. <i>CardioVascular and Interventional Radiology</i> , 2019 , 42, 239-249	2.7	14
439	Reason of Discontinuation After Transarterial Chemoembolization Influences Survival in Patients with Hepatocellular Carcinoma. <i>CardioVascular and Interventional Radiology</i> , 2019 , 42, 230-238	2.7	5
438	Histological findings in non-tumoral liver and tumor after chemoembolization with drug-eluting beads. 2020 , 29, 217-223		1
437	Influence of pretreatment tumor growth rate on objective response of hepatocellular carcinoma treated with transarterial chemoembolization. 2020 , 35, 305-313		8
436	Drug Release Property of Lipiodol Emulsion Formed by Glass Membrane Emulsification Device for Transarterial Chemoembolization. <i>CardioVascular and Interventional Radiology</i> , 2020 , 43, 135-139	2.7	4
435	Long-Term Outcomes of Transarterial Chemoembolization Combined with Radiofrequency Ablation Versus Transarterial Chemoembolization Alone for Recurrent Hepatocellular Carcinoma After Surgical Resection. 2020 , 65, 1266-1275		4
434	Transarterial Chemoembolization of Hepatocellular Carcinoma: Propensity Score Matching Study Comparing Survival and Complications in Patients with Nonalcoholic Steatohepatitis Versus Other Causes Cirrhosis. <i>CardioVascular and Interventional Radiology</i> , 2020 , 43, 65-75	2.7	2
433	Transarterial Chemoembolisation (TACE) with Degradable Starch Microspheres (DSM) and Anthracycline in Patients with Locally Extensive Hepatocellular Carcinoma (HCC): Safety and Efficacy. <i>CardioVascular and Interventional Radiology</i> , 2020 , 43, 402-410	2.7	7
432	Liver and Bile Duct Cancer. 2020 , 1314-1341.e11		3

431	Sustained release of arsenic trioxide benefits interventional therapy on rabbit VX2 liver tumor. 2020 , 24, 102118		6
430	CT-Based Hepatic Residual Volume and Predictors of Outcomes of Patients with Hepatocellular Carcinoma Unsuitable for Surgical Therapy Undergoing Transarterial Chemoembolization. 2020 , 27, 807-814		3
429	Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma. <i>CardioVascular and Interventional Radiology</i> , 2020 , 43, 55-64	2.7	14
428	[Locoregional and local ablative treatment options for liver tumors]. 2020 , 61, 158-163		1
427	Quantification of Functional MR Predicts Early Response in Post-doxorubicin Drug-Eluting Beads Chemoembolization for Hepatocellular Carcinoma. 2020 , 65, 2433-2441		2
426	Transarterial chemoembolization for hepatocellular carcinoma: quality of life, tumour response, safety and survival comparing two types of drug-eluting beads. 2020 , 45, 3326-3336		2
425	Locoregional Therapies for Hepatocellular Carcinoma: What Has Changed in the Past Ten Years?. 2020 , 24, 681-700		2
424	Drug-eluting Bead-Transcatheter Arterial Chemoembolization for Advanced Hepatocellular Carcinoma Refractory to Conventional Lipiodol-based Transcatheter Arterial Chemoembolization. 2020 , 7, 181-189		2
423	Locoregional Therapy Approaches for Hepatocellular Carcinoma: Recent Advances and Management Strategies. 2020 , 12,		23
422	Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study. 2021 , 217, 933-943		10
421	Real Life Prospective Evaluation of New Drug-Eluting Platform for Chemoembolization of Patients with Hepatocellular Carcinoma: PARIS Registry. 2020 , 12,		4
420	Efficacy and Safety of Supplemental Transarterial Chemoembolization Through Extrahepatic Collateral Arteries with Drug-eluting Beads: Treatment for Unresectable Hepatocellular Carcinoma. 2020 , 14, 5029-5041		3
419	In vivo evaluation of a monodisperse solid-in-oil-in-water miriplatin/ lipiodol emulsion in transcatheter arterial chemoembolization using a rabbit VX2 tumor model. 2020 , 15, e0222553		2
418	Nanosized drug-eluting bead for transcatheter arterial chemoembolization (ND-TACE). 2020 , 8, 8684-8694		1
417	A novel application of drug-eluting transarterial chemoembolization in treating non-liver cancers. 2020 , 99, e20878		1
416	Malignant liver tumours. 2020 , 38, 480-486		1
415	Advances in the treatment of hepatocellular carcinoma using drug-eluting beads. 2020 , 3, 122-127		2
414	Treatment Strategy of Transarterial Chemoembolization for Hepatocellular Carcinoma. 2020 , 10, 7337		3

413	Lack of Technique Standardization Limits Evaluation of Toxicity following Transarterial Chemoembolization. 2020 , 31, 1300-1301	1
412	Comparison of Opioid Medication Use after Conventional Chemoembolization versus Drug-Eluting Embolic Chemoembolization. 2020 , 31, 1292-1299	3
411	Clinical management of vascular lake during transarterial chemoembolization with CalliSpheres drug-eluting beads (DEBs) for the treatment of hepatocellular carcinoma.. 2020 , 9, 2895-2903	1
410	Sodium Cholate Bile Acid-Stabilized Ferumoxytol-Doxorubicin-Lipiodol Emulsion for Transcatheter Arterial Chemoembolization of Hepatocellular Carcinoma. 2020 , 31, 1697-1705.e3	3
409	Prognostic value of vascular endothelial growth factor in both conventional and drug eluting beads transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma in HCV patients. 2020 , 14, 1203-1214	9
408	Comparison of embolic effect between water-in-oil emulsion and microspheres in transarterial embolization for rat hepatocellular carcinoma model. 2020 , 50, 1297-1305	4
407	Current locoregional therapies and treatment strategies in hepatocellular carcinoma. 2020 , 27, S144-S151	7
406	Diagnosis, Staging, and Patient Selection for Locoregional Therapy to Treat Hepatocellular Carcinoma. 2020 , 37, 441-447	2
405	Management of patients with intermediate stage hepatocellular carcinoma. 2020 , 12, 1758835920970840	9
404	Recent Updates of Transarterial Chemoembolization in Hepatocellular Carcinoma. 2020 , 21,	35
403	Multi-modal and sequential treatment of liver cancer and its impact on the gastrointestinal tract. 2020 , 48-49, 101709	1
402	Radiopaque beads loaded with doxorubicin in the treatment of patients with hepatocellular carcinoma: A retrospective, multi-center study. 2020 , 25, 100208	1
401	Aldehyde-Functionalized Magnetic Particles to Capture Off-Target Chemotherapeutic Agents. 2020 , 5, 29121-29126	2
400	Hepatocellular Carcinoma: A Contemporary Approach to Locoregional Therapy. 2020 , 115, 1733-1736	0
399	The Comprehensive Analysis of Efficacy and Safety of CalliSpheres Drug-Eluting Beads Transarterial Chemoembolization in 367 Liver Cancer Patients: A Multiple-Center, Cohort Study. 2020 , 28, 249-271	9
398	Efficacy evaluation of the combination therapy of sorafenib and transarterial chemoembolization for unresectable HCC: a systematic review and meta-analysis of comparative studies. 2020 , 8, 540	2
397	In situ forming implants exposed to ultrasound enhance therapeutic efficacy in subcutaneous murine tumors. 2020 , 324, 146-155	3
396	Drug-Eluting Microsphere Versus Cisplatin-Based Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma: Propensity Score-Matched Analysis. 2020 , 215, 745-752	2

395	Nonsurgical management of advanced hepatocellular carcinoma: a clinical practice guideline. 2020 , 27, e106-e114	5
394	The development of early ascites is associated with shorter overall survival in patients with hepatocellular carcinoma treated with drug-eluting embolic chemoembolization. 2020 , 20, 166	3
393	PKM2 inhibition may reverse therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma. 2020 , 39, 99	16
392	Molecular Imaging and Therapy of Liver Tumors. 2020 , 50, 419-433	1
391	Transarterial chemoembolization with medium-sized doxorubicin-eluting Callispheres is safe and effective for patients with hepatocellular carcinoma. 2020 , 10, 4434	8
390	Fabrication of radiopaque drug-eluting beads based on Lipiodol/biodegradable-polymer for image-guided transarterial chemoembolization of unresectable hepatocellular carcinoma. 2020 , 175, 109106	6
389	Silk Particle Production Based on silk/PVA Phase Separation Using a Microfabricated Co-flow Device. 2020 , 25,	6
388	Emerging Opportunities for Combining Locoregional Therapy with Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. 2020 , 22, 76	1
387	DNA-PK in human malignant disorders: Mechanisms and implications for pharmacological interventions. 2020 , 215, 107617	12
386	Is it Rational to Perform Liver Resection for Patients with Intermediate and Advanced Stages of Hepatocellular Carcinoma?. 2020 , 86, 313-323	3
385	Efficacy of combined bland embolization and chemoembolization for huge (≥10 cm) hepatocellular carcinoma. 2021 , 30, 221-228	5
384	Comparison of chemoembolization with CalliSpheres microspheres and conventional chemoembolization in the treatment of hepatocellular carcinoma: a multicenter retrospective study. 2020 , 12, 941-956	12
383	Updates of colorectal cancer liver metastases therapy: review on DEBIRI. 2020 , 7, HEP16	17
382	Suitability of the woodchuck HCC as a preclinical model for evaluation of intra-arterial therapies. 2020 , 3, 98-102	2
381	Comparative Analysis of Safety and Efficacy of Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma in Patients with and without Pre-Existing Transjugular Intrahepatic Portosystemic Shunts. 2020 , 31, 409-415	4
380	Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. 2020 , 31, 334-351	64
379	Transarterial strategies for the treatment of unresectable hepatocellular carcinoma: A systematic review. 2020 , 15, e0227475	16
378	Targeting DNA-PK in cancer. 2020 , 821, 111692	25

377	Predictive performance of the mHAP-II score in a real-life western cohort with hepatocellular carcinoma following trans-arterial chemoembolisation with drug-eluting beads (DEB-TACE). 2020 , 30, 3782-3792	6
376	Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization by CalliSpheres in 275 Hepatocellular Carcinoma Patients: Results From the Chinese CalliSpheres Transarterial Chemoembolization in Liver Cancer (CTILC) Study. 2020 , 28, 75-94	9
375	Hepatocellular Carcinoma-How to Determine Therapeutic Options. 2020 , 4, 342-354	8
374	Predicting survival after transarterial chemoembolization for hepatocellular carcinoma using a neural network: A Pilot Study. 2020 , 40, 694-703	18
373	Stereotactic Body Radiation Therapy vs. Transarterial Chemoembolization in Inoperable Barcelona Clinic Liver Cancer Stage a Hepatocellular Carcinoma: A Retrospective, Propensity-Matched Analysis. 2020 , 10, 347	9
372	Multicentre prospective study of drug-eluting bead chemoembolisation safety using tightly calibrated small microspheres in non-resectable hepatocellular carcinoma. 2020 , 126, 108966	6
371	Increased Survival Benefit of Adjuvant Intra-arterial Infusion Chemotherapy in HCC Patients with Portal Vein Infiltration after Hepatectomy. 2020 , 44, 2770-2776	4
370	Locoregional Therapies in the Treatment of 3- to 5-cm Hepatocellular Carcinoma: Critical Review of the Literature. 2020 , 215, 223-234	5
369	Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. 2021 , 73 Suppl 1, 158-191	63
368	Local and Regional Therapies for Hepatocellular Carcinoma. 2021 , 73 Suppl 1, 137-149	25
367	Transarterial chemoembolization with drug-eluting beads in patients with hepatocellular carcinoma: response analysis with mRECIST. 2021 , 27, 85-93	1
366	Interventional radiology for liver diseases. 2021 , 31, 2227-2230	3
365	Prospective study of Lipiodol distribution as an imaging marker for doxorubicin pharmacokinetics during conventional transarterial chemoembolization of liver malignancies. 2021 , 31, 3002-3014	6
364	Interventional neuro-oncology. 2021 , 176, 361-378	0
363	Balloon-occluded chemoembolization for hepatocellular carcinoma: a prospective study of safety, feasibility and outcomes. 2020 , 8, HEP31	2
362	Huge hepatocellular carcinoma with extrahepatic collateral arteries successfully treated by multidisciplinary treatment including laparoscopic devascularization: a case report. 2021 , 14, 251-257	
361	Conventional versus drug-eluting bead transarterial chemoembolization: A better option for treatment of unresectable hepatocellular carcinoma. 2021 , 4, 11-14	2
360	Predictive factors of severe abdominal pain during and after transarterial chemoembolization for hepatocellular carcinoma. 2021 , 31, 3267-3275	0

359	Response rate and safety in patients with hepatocellular carcinoma treated with transarterial chemoembolization using 40-µm doxorubicin-eluting microspheres. 2021 , 147, 23-32	5
358	Adding Sorafenib-eluting Microspheres to TACE: The Next Step in Hepatocellular Carcinoma Treatment. 2021 , 3, e200132	
357	Optimizing the Combination of Immunotherapy and Trans-Arterial Locoregional Therapy for Stages B and C Hepatocellular Cancer. 2021 , 28, 1499-1510	1
356	Cost-Effectiveness of Imaging Tumor Response Criteria in Hepatocellular Cancer After Transarterial Chemoembolization. 2021 , 18, 927-934	1
355	A novel irinotecan-lipiodol nanoemulsion for intravascular administration: pharmacokinetics and biodistribution in the normal and tumor bearing rat liver. 2021 , 28, 240-251	2
354	Whole-liver transcatheter arterial chemoinfusion and bland embolization with fine-powder cisplatin and trisacryl gelatin microspheres for treating unresectable multiple hepatocellular carcinoma. 2021 , 39, 494-502	1
353	Updates on the Diagnosis and Management of Hepatocellular Carcinoma. 2021 , 11, 32-40	3
352	Long Noncoding RNA SOX2-OT Aggravates Doxorubicin-Induced Apoptosis of Cardiomyocyte by Targeting miR-942-5p/DP5. 2021 , 15, 481-492	4
351	Treatment stage migration and treatment sequences in patients with hepatocellular carcinoma: drawbacks and opportunities. 2021 , 147, 2471-2481	3
350	A change in the timing for starting systemic therapies for hepatocellular carcinoma: the comparison of sorafenib and lenvatinib as the first-line treatment. 2021 , 84, 65-72	0
349	Survival and Outcome in Patients Receiving Drug-Eluting Beads Transarterial Chemoembolization for Large Hepatocellular Carcinoma (>5 cm). 2021 , 11, 674-681	1
348	Transarterial chemoembolisation in patients with hepatocellular carcinoma: low-dose doxorubicin reduces post-embolisation syndrome without affecting survival-prospective interventional study. 2021 , 5, 10	1
347	Hepatocellular carcinoma: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, AFEF, SIAD, SFR/FRI). 2021 , 45, 101590	2
346	Locoregional Therapies for Bridging and Downstaging Hepatocellular Carcinoma Prior to Liver Transplant. 127-144	
345	Comparison of the efficacy and safety of conventional transarterial chemoembolization with and without drug-eluting beads embolization for the treatment of unresectable large hepatocellular carcinoma. 2021 , 51, 482-489	0
344	Retrospective European Multicentric Evaluation of Selective Transarterial Chemoembolisation with and without Balloon-Occlusion in Patients with Hepatocellular Carcinoma: A Propensity Score Matched Analysis. <i>CardioVascular and Interventional Radiology</i> , 2021 , 44, 1048-1059	2.7 6
343	Treatment Response, Survival, and Safety of Transarterial Chemoembolization With CalliSpheres Microspheres Versus Conventional Transarterial Chemoembolization in Hepatocellular Carcinoma: A Meta-Analysis. 2021 , 11, 576232	5
342	Quantitative assessment of HCC wash-out on CT is a predictor of early complete response to TACE. 2021 , 31, 6578-6588	4

341	Efficacy of Stereotactic Body Radiotherapy in Patients With Hepatocellular Carcinoma Not Suitable for Transarterial Chemoembolization (HERACLES: Hepatocellular Carcinoma Stereotactic Radiotherapy Clinical Efficacy Study). 2021 , 11, 653141	1
340	LI-RADS treatment response algorithm after first-line DEB-TACE: reproducibility and prognostic value at initial post-treatment CT/MRI. 2021 , 46, 3708-3716	1
339	Duration of response after DEB-TACE compared to lipiodol-TACE in HCC-naïve patients: a propensity score matching analysis. 2021 , 31, 7512-7522	3
338	Safety and Efficacy of Degradable Starch Microspheres Transcatheter Arterial Chemoembolization as a Bridging Therapy in Patients with Early Stage Hepatocellular Carcinoma and Child-Pugh Stage B Eligible for Liver Transplant. 2021 , 12, 634084	4
337	Drug-eluting beads TACE is safe and non-inferior to conventional TACE in HCC patients with TIPS. 2021 , 31, 8291-8301	2
336	Initial Transarterial Chemoembolization (TACE) Using HepaSpheres 20-40 µm and Subsequent Lipiodol TACE in Patients with Hepatocellular Carcinoma > 5 cm. 2021 , 11,	
335	Tumor Biomarkers and Interventional Oncology: Impact on Local Outcomes for Liver and Lung Malignancy. 2021 , 23, 67	3
334	Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects. 2021 , 27, 236-245	7
333	Chinese expert consensus on technical recommendations for the standard operation of drug-eluting beads for transvascular embolization. 2021 , 9, 714	5
332	Downstaging treatment for patients with hepatocellular carcinoma before transplantation. 2021 , 35, 100606	1
331	Therapies for hepatocellular carcinoma: overview, clinical indications, and comparative outcome evaluation. Part two: noncurative intention. 2021 , 46, 3540-3548	2
330	Safety and Efficacy of Degradable Starch Microspheres Transcatheter Arterial Chemoembolization (DSM-TACE) in the Downstaging of Intermediate-Stage Hepatocellular Carcinoma (HCC) in Patients With a Child-Pugh Score of 8-9. 2021 , 12, 634087	2
329	Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. 2021 , 156, 463.e1-463.e30	2
328	Drug-eluting bead chemoembolization for the treatment of nonresectable hepatic carcinoma in dogs: A prospective clinical trial. 2021 , 35, 1487-1495	2
327	Current Strategies to Identify Patients That Will Benefit from TACE Treatment and Future Directions a Practical Step-by-Step Guide. 2021 , 8, 403-419	10
326	The impact of portal vein tumor thrombosis on survival in patients with hepatocellular carcinoma treated with different therapies: A cohort study. 2021 , 16, e0249426	5
325	Advances in systemic therapy for the first-line treatment of unresectable HCC. 2021 , 21, 621-628	3
324	Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. 2021 , 156, 463.e1-463.e30	0

323	Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update. 2021 , 10, 181-223	38
322	Phase I Trial on Arterial Embolization with Hypoxia Activated Tirapazamine for Unresectable Hepatocellular Carcinoma. 2021 , 8, 421-434	4
321	Immunonutritive Scoring in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Prognostic Nutritional Index or Controlling Nutritional Status Score?. 2021 , 11, 696183	11
320	Transarterial Chemoembolization of Hepatocellular Carcinoma with Oncozene Microspheres: An Initial, Short-Term Clinical Experience-A Retrospective, Matched, Comparison Study. 2021 , 11,	
319	Advances in Diagnostic and Interventional Radiology in Hepatocellular Carcinoma. 2021 ,	0
318	Locoregional therapy in hepatocellular carcinoma: when to start and when to stop and when to revisit. 2021 , 6, 100129	2
317	Hepatocellular Carcinoma and the Role of Liver Transplantation: A Review. 2021 , 9, 738-748	2
316	Locoregional therapies for the treatment of locally advanced hepatocellular carcinoma. 2021 , 54, IX-X	
315	Complete Response of Hepatocellular Carcinoma with Macroscopic Vascular Invasion and Pulmonary Metastasis to the Combination of Drug-Eluting Beads Transarterial Chemoembolization and Huaier Granule: A Case Report. 2021 , 14, 3873-3880	2
314	Redefining Intermediate-Stage HCC Treatment in the Era of Immune Therapies. 2021 , OP2100227	1
313	Addressing the worldwide hepatocellular carcinoma: epidemiology, prevention and management. 2021 , 12, S361-S373	6
312	Consensus of Minimally Invasive and Multidisciplinary Comprehensive Treatment for Hepatocellular Carcinoma - 2020 Guangzhou Recommendations. 2021 , 11, 621834	1
311	Traditional versus Microsphere Embolization for Hepatocellular Carcinoma: An Effectiveness Evaluation Using Data Mining. 2021 , 9,	1
310	Evaluation of Hepatocellular Carcinoma Treatment Response After Locoregional Therapy. 2021 , 29, 389-403	0
309	Advances in locoregional therapy for hepatocellular carcinoma combined with immunotherapy and targeted therapy. 2021 , 4, 105-113	3
308	Refining Prognosis in Chemoembolization for Hepatocellular Carcinoma: Immunonutrition and Liver Function. 2021 , 13,	2
307	Recommandation opérationnelle en radiologie interventionnelle : chimioembolisation hépatique. 2021 , 4, 357-357	
306	Transcatheter Arterial Chemoembolization with Drug-Eluting Beads for the Treatment of Hepatocellular Carcinoma: Recommended Selection for Small-Caliber (. 2021 , 8, 937-949	3

305	Prediction of transarterial chemoembolization (TACE) outcome by pre- and postinterventional ¹³ C-methacetin breath test. 2021 , 79, 73-80	0
304	Recent advances and applications of microspheres and nanoparticles in transarterial chemoembolization for hepatocellular carcinoma. 2021 , e1749	0
303	Unresectable hepatocellular carcinoma treatment with doxorubicin-eluting polyethylene glycol microspheres: a single-center experience. 2021 , 8, HEP38	0
302	Portal Vein Tumor Thrombosis and Hepatocellular Carcinoma - The Changing Tides. 2021 , 8, 1089-1115	2
301	Transarterial chemoembolization using drug-eluting bead compared with radiofrequency ablation for treatment of single small hepatocellular carcinoma: a pilot non-randomized trial. 2021 , 21, 146-154	0
300	Gas generating microspheres for immediate release of Hsp90 inhibitor aiming at postembolization hypoxia in transarterial chemoembolization therapy of hepatocellular carcinoma. 2021 , 607, 120988	1
299	SOP Transarterielle Chemoembolisation zur Tumorthherapie. 2021 , 3, 189-195	
298	Efficacy of Combined Therapy with Drug-Eluting Beads-Transcatheter Arterial Chemoembolization Followed by Conventional Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multi-Center Study. 2021 , 13,	0
297	Paradigm shift in the treatment options of hepatocellular carcinoma. 2021 ,	3
296	Drug-eluting bead transarterial chemoembolization (TACE) exhibits superior efficacy and equal tolerance to conventional TACE in hepatocellular carcinoma patients with conventional TACE history. 2021 , 46, 101814	1
295	Combination of transcatheter arterial chemoembolization and portal vein embolization for patients with hepatocellular carcinoma: a review. 2021 , 19, 293	2
294	Clinical practice of transarterial chemoembolization for hepatocellular carcinoma: consensus statement from an international expert panel of International Society of Multidisciplinary Interventional Oncology (ISMIO). 2021 , 10, 661-671	4
293	Application of iron/barium ferrite/carbon-coated iron nanocrystal composites in transcatheter arterial chemoembolization of hepatocellular carcinoma. 2021 , 601, 30-41	1
292	Drug-eluting embolic microspheres: State-of-the-art and emerging clinical applications. 2021 , 18, 383-398	5
291	Comparison of Drug-Eluting Embolics versus Conventional Transarterial Chemoembolization for the Treatment of Patients with Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. 2021 , 32, 2-12.e1	3
290	Prospective Multi-Center Korean Registry of Transcatheter Arterial Chemoembolization with Drug-Eluting Embolics for Nodular Hepatocellular Carcinoma: A Two-Year Outcome Analysis. 2021 , 22, 1658-1670	2
289	Transcatheter Arterial Embolization Using Microspheres for Palliating Pain from Bone Metastasis in a Patient with Cholangiocellular Carcinoma. 2021 , 60, 241-246	
288	Local Efficacy and Safety of Transarterial Chemoembolization for Hepatocellular Carcinoma: Epirubicin-Loaded DC Beads vs. Epirubicin-Lipiodol Emulsion with Gelatin Sponge (cTACE). 2021 , 6, 14-20	

287	Magnetic liquid metal loaded nano-in-micro spheres as fully flexible theranostic agents for SMART embolization. 2021 , 13, 8817-8836	10
286	Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. 2021 , 18, 293-313	80
285	Hepatocellular carcinoma. 2021 , 7, 6	563
284	Balloon-Occluded Transarterial Chemoembolization: In Which Size Range Does It Perform Best? A Comparison of Its Efficacy versus Conventional Transarterial Chemoembolization, Using Propensity Score Matching. 2021 , 10, 522-534	1
283	Other Bridge Therapies for Liver Transplantation: RFA, TACE, and TARE. 2020 , 183-191	1
282	Medical Therapy of HCC. 2016 , 489-512	1
281	Transarterial therapies for hepatocellular carcinoma. 2013 , 190, 195-206	13
280	HCC. 2015 , 31-54	1
279	Idarubicin-Loaded ONCOZENE Drug-Eluting Bead Chemoembolization in a Rabbit Liver Tumor Model: Investigating Safety, Therapeutic Efficacy, and Effects on Tumor Microenvironment. 2020 , 31, 1706-1716.e1	2
278	SOP Transarterielle Chemoembolisation zur Tumorthherapie. 2020 , 16, 201-208	1
277	In vitro evaluation of doxorubicin-eluting porous titania microspheres for transcatheter arterial chemoembolization. 2020 , 8, 10-20	1
276	Single-center randomized trial comparing conventional chemoembolization versus doxorubicin-loaded polyethylene glycol microspheres for early- and intermediate-stage hepatocellular carcinoma. 2021 , 30, 258-266	1
275	Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy. 2012 , 24, 437-43	92
274	Treatment of Hepatoblastoma With Drug-eluting Bead Transarterial Chemoembolization in a 13-Month-Old Infant: A Case Report and Review of the Literature. 2021 , 43, e123-e126	2
273	Selective DNA-PKcs inhibition extends the therapeutic index of localized radiotherapy and chemotherapy. 2020 , 130, 258-271	22
272	One-step, Rapid and Green Synthesis of Multifunctional Gold Nanoparticles for Tumor-Targeted Imaging and Therapy. 2020 , 15, 29	3
271	Assessment of hepatocellular carcinoma treatment response with LI-RADS: a pictorial review. 2019 , 10, 121	18
270	Hepatocellular carcinoma: recent advances and emerging medical therapies. 2020 , 9,	21

269	Tumor angiogenesis after heated lipiodol infusion via the hepatic artery in a rabbit model of VX2 liver cancer. 2013 , 8, e61583	11
268	Does drug-eluting bead transcatheter arterial chemoembolization improve the management of patients with hepatocellular carcinoma? A meta-analysis. 2014 , 9, e102686	21
267	Short-term imaging response after drug-eluting embolic trans-arterial chemoembolization delivered with the Surefire Infusion System [®] for the treatment of hepatocellular carcinoma. 2017 , 12, e0183861	4
266	Role of Locoregional Therapies in Patients With Hepatocellular Cancer Awaiting Liver Transplantation. 2021 , 116, 57-67	7
265	RECOMMENDATIONS FOR INVASIVE PROCEDURES IN PATIENTS WITH DISEASES OF THE LIVER AND BILIARY TRACT: REPORT OF A JOINT MEETING OF THE BRAZILIAN SOCIETY OF HEPATOLOGY (SBH), BRAZILIAN SOCIETY OF DIGESTIVE ENDOSCOPY (SOBED) AND BRAZILIAN SOCIETY OF INTERVENTIONAL RADIOLOGY AND ENDOVASCULAR SURGERY (SOBRICE). 2019 , 56, 213-231	2
264	BRAZILIAN SOCIETY OF HEPATOLOGY UPDATED RECOMMENDATIONS FOR DIAGNOSIS AND TREATMENT OF HEPATOCELLULAR CARCINOMA. 2020 , 57, 1-20	10
263	A mixed analysis comparing nine minimally invasive surgeries for unresectable hepatocellular carcinoma patients. 2017 , 8, 5460-5473	1
262	Comparing the long-term efficacy of standard and combined minimally invasive procedures for unresectable HCC: a mixed treatment comparison. 2017 , 8, 15101-15113	14
261	Classification and Current Treatment of Hepatocellular Carcinoma. 2, 8	2
260	2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. 2019 , 20, 1042-1113	96
259	Recent advances in transarterial embolotherapies in the treatment of hepatocellular carcinoma. 2017 , 23, 265-272	28
258	Switching to systemic therapy after locoregional treatment failure: Definition and best timing. 2020 , 26, 155-162	21
257	Optimal technique and response of doxorubicin beads in hepatocellular cancer: bead size and dose. 2011 , 17, 51-60	24
256	Doxorubicin-eluting bead vs conventional transcatheter arterial chemoembolization for hepatocellular carcinoma before liver transplantation. 2013 , 19, 5622-32	44
255	Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation. 2013 , 19, 7515-30	80
254	Neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation: where do we stand?. 2014 , 20, 5308-19	22
253	Current management of hepatocellular carcinoma. 2014 , 20, 10223-37	56
252	Diabetes mellitus and metformin in hepatocellular carcinoma. 2016 , 22, 6100-13	44

251	Combined locoregional treatment of patients with hepatocellular carcinoma: State of the art. 2016 , 22, 1935-42	46
250	Intermediate-advanced hepatocellular carcinoma in Argentina: Treatment and survival analysis. 2019 , 25, 3607-3618	10
249	Locoregional treatments for hepatocellular carcinoma: Current evidence and future directions. 2019 , 25, 4614-4628	42
248	Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging. 2019 , 25, 5687-5701	11
247	Validation of the six-and-twelve criteria among patients with hepatocellular carcinoma and performance score 1 receiving transarterial chemoembolization. 2020 , 26, 1805-1819	2
246	Idarubicin doxorubicin in transarterial chemoembolization of intermediate stage hepatocellular carcinoma. 2020 , 26, 324-334	4
245	Safety Profile and Efficacy of Chemoembolization with Doxorubicin - Loaded Polyethylene Glycol Microspheres in Patients with Hepatocellular Carcinoma. 2019 , 7, 742-746	3
244	Efficacy and safety of drug-eluting beads for transarterial chemoembolization in patients with advanced hepatocellular carcinoma. 2019 , 18, 4625-4630	4
243	Indication of suitable transarterial chemoembolization and multikinase inhibitors for intermediate stage hepatocellular carcinoma. 2020 , 19, 2667-2676	4
242	Lenvatinib prolongs the progression-free survival time of patients with intermediate-stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysis. 2020 , 20, 2257-2265	22
241	Transcatheter embolization therapy in liver cancer: an update of clinical evidences. 2015 , 27, 96-121	51
240	C-arm dual-phase cone-beam CT: a revolutionary real-time imaging modality to assess drug-eluting beads TACE success in liver cancer patients. 2013 , 3, 196-9	11
239	Doxorubicin-loaded drug-eluting beads versus conventional transarterial chemoembolization for nonresectable hepatocellular carcinoma. 2015 , 21, 175-80	33
238	Hepatocellular carcinoma Liver Imaging Reporting and Data Systems treatment response assessment: Lessons learned and future directions. 2020 , 12, 738-753	6
237	Management of hepatocellular carcinoma: Enlightening the gray zones. 2013 , 5, 302-10	29
236	Multidisciplinary perspective of hepatocellular carcinoma: A Pacific Northwest experience. 2015 , 7, 1460-83	14
235	Update in management of hepatocellular carcinoma in Eastern population. 2015 , 7, 1562-71	19
234	Circulating biomarkers of hepatocellular carcinoma response after locoregional treatments: New insights. 2015 , 7, 1834-42	10

233	Image-guided therapies in the treatment of hepatocellular carcinoma: A multidisciplinary perspective. 2015 , 7, 235-44	7
232	Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols. 2015 , 7, 2274-91	39
231	Recommendations for the use of chemoembolization in patients with hepatocellular carcinoma: Usefulness of scoring system?. 2015 , 7, 521-31	7
230	Treatment of hepatocellular carcinoma: Steps forward but still a long way to go. 2015 , 7, 566-74	38
229	Survival rates according to barcelona clinic liver cancer sub-staging system after transarterial embolization for intermediate hepatocellular carcinoma. 2015 , 7, 628-32	15
228	Recent advances in multidisciplinary management of hepatocellular carcinoma. 2015 , 7, 673-87	67
227	Transarterial radioembolization vs chemoembolization for hepatocarcinoma patients: A systematic review and meta-analysis. 2016 , 8, 770-8	42
226	Locoregional treatment for hepatocellular carcinoma: The best is yet to come. 2015 , 7, 306-18	18
225	Development of biodegradable radiopaque microsphere for arterial embolization-a pig study. 2015 , 7, 212-9	10
224	Transarterial chemoembolization using 40 µm drug eluting beads for hepatocellular carcinoma. 2017 , 9, 245-252	18
223	DC Bead Transarterial Chemoembolization Is Effective in Hepatocellular Carcinoma Refractory to Conventional Transarterial Chemoembolization: A Pilot Study. 2013 , 7, 89-95	17
222	Management of Hepatocellular Carcinoma: Current Status and Future Directions. 2015 , 9, 437-48	41
221	2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. 2019 , 13, 227-299	151
220	Saudi guidelines for the diagnosis and management of hepatocellular carcinoma: technical review and practice guidelines. 2012 , 32, 174-99	19
219	Super-Selective Transarterial Chemoembolization with Doxorubicin-Loaded Drug-Eluting Beads Sized Below and Above 100 Microns in Hepatocellular Carcinoma: A Comparative Study. 2019 , 103, 47	8
218	Hepatocellular carcinoma—100 most influential manuscripts: A bibliometric analysis. 2019 , 9, 1	4
217	Loco-regional therapies for patients with hepatocellular carcinoma awaiting liver transplantation: Selecting an optimal therapy. 2016 , 6, 306-13	11
216	Interventional Radiologic Treatment of Hepatocellular Carcinoma. 2017 , 15, 25-30	7

215	Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. 2021 , 19, 541-565	74
214	Transarterial Therapies for Hepatocellular Carcinoma: a Comprehensive Review with Current Updates and Future Directions. 2016 , 17, 473-8	23
213	In the Era of Systemic Therapy for Hepatocellular Carcinoma Is Transarterial Chemoembolization Still a Card to Play?. 2021 , 13,	0
212	Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial. 2021 , JCO2100608	15
211	Biodegradable poly(lactide-co-glycolide) microspheres encapsulating hydrophobic contrast agents for transarterial chemoembolization. 2021 , 1-17	1
210	CIRSE Standards of Practice on Hepatic Transarterial Chemoembolisation. <i>CardioVascular and Interventional Radiology</i> , 2021 , 44, 1851-1867	2.7 7
209	Immunonutritive Scoring for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Evaluation of the CALLY Index. 2021 , 13,	2
208	Abdominal Vascular Disease: Diagnosis and Therapy. 2010 , 154-161	
207	A case of hepatocellular carcinoma in the caudate lobe successfully treated by transcatheter arterial chemoembolization using drug-eluting beads. 2010 , 16, 405-9	1
206	Efficacy of Novel Transcatheter Arterial Therapy for Hepatocellular Carcinoma. 2011 , 60, 173-178	1
205	Interventional approaches to treatment in supportive oncology. 2011 , 382-389	
204	Hepatocellular Carcinoma. 978-989	
203	Principles of Liver Embolization. 2012 , 95-106	1
202	Are Drug-Eluting Beads Worth using?. 136-141	
201	Emerging Therapies for Hepatocellular Carcinoma. 2012 , 263-290	
200	Treatment of HCC: Resection, Local-Regional Therapy, Systemic Therapy, and Liver Transplantation. 2012 , 199-214	
199	Recurrence: Prevention and Management. 2012 , 215-227	
198	Interventional Imaging in the Oncologic Patient. 2012 , 667-677	

- 197 Applications of Medical Implant Materials. **2012**, 18-35 2
- 196 Current Status of Hepatocellular Carcinoma Treatment in Japan. **2012**, 32, 3-13
- 195 30 cycles of Trans-Arterial Chemoembolisation prolonged survival in a patient with multiple recurrent hepatocellular carcinoma. **2013**, 54, 391-395
- 194 Chemoembolization and Radioembolization in the Treatment of Primary Liver Cancers. **2013**, 327-338
- 193 Transvaskuläre Therapie des hepatozellulären Karzinoms. **2013**, 299-322 1
- 192 Hepatic Tumors: An Oncologist's Perspective. 273-282
- 191 Chemoembolizations and Hepatic Intra-arterial Chemotherapies. **2014**, 115-133
- 190 Tumor Embolization: Embolization of Liver Tumors. **2014**, 897-903
- 189 Interventional Radiology Management of Unresectable Intrahepatic Cholangiocarcinoma. **2014**, 201-223
- 188 Liver and Bile Duct Cancer. **2014**, 1373-1396.e8 1
- 187 Liver-Directed Therapies in Neuroendocrine Tumors. **2014**, 95-114
- 186 Embolization Materials, Catheters, and Intra-arterial Ports. **2015**, 19-28
- 185 Hepatocellular Carcinoma. **2015**, 335-352
- 184 Diagnostische und therapeutische Verfahren in der Viszeralmedizin. **2015**, 37-68
- 183 Liver-Directed Therapies in Neuroendocrine Tumors. **2015**, 475-489
- 182 Use of Initial Modified RECIST Tumor Response Evaluation Criteria for Predicting Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization with Drug-Eluting Beads. **2015**, 06, 1115-1123
- 181 [Transarterial therapy for hepatocellular cancer]. **2015**, 43-49
- 180 Hepatocellular cancer and venous thromboembolism. **2015**, 109-120

- 179 Early-stage hepatocellular carcinoma: the percutaneous approach. **2015**, 217-224
- 178 HEPATOCELIULINŲ KARCINOMOS GYDYMO TRANSARTERINE CHEMOEMBOLIZACIJA DOKSORUBICINU IMPREGNUOTOMIS MIKROSFEROMIS (DEB TACE) LIETUVOS SVEIKATOS MOKSLŲ UNIVERSITETO LIGONINŲ KAUANO KLINIKOSE ANALIZĖ **2015**, 21, 559-565
- 177 Trans-arterial Chemo-Embolization in Treating Elderly Patients with Hepatocellular Carcinoma. **2015**, 16, 7201-4
- 176 From Tracing the History of Medical Therapies to the Development of Novel Therapies for Hepatocellular Carcinoma. **2016**, 65, 15-22
- 175 Role of Neoadjuvant and Adjuvant Treatment in HCC Recurrence After Liver Transplantation. **2016**, 187-203
- 174 9. Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma. **2016**, 72, 1039-1048
- 173 Chemoembolization With Drug-Eluting Beads for the Treatment of Hepatocellular Carcinoma. **2016**, 7, 764-778 1
- 172 Hepatic Arterial Infusion Chemotherapy with Cisplatin for TACE-Refractory or -Ineligible Hepatocellular Carcinoma with Child-Pugh Score of 8 or Above. **2017**, 17,
- 171 Two cases of the hepatocellular carcinoma with portal vein tumor thrombus treated with DEB-TACE effectively. **2017**, 58, 28-37 1
- 170 Pretransplant Evaluation and Care. **2018**, 737-752.e5
- 169 Hepatocellular Carcinoma. **2018**, 668-692.e9 1
- 168 Locoregional Therapies in the Management of Hepatocellular Carcinoma. **2018**, 57-72
- 167 Influence of injection mode and antioxidant dietary on the toxicity of Doxorubicin as a chemotherapy drug. **2018**, 9,
- 166 Transarterial Embolization Therapies in Hepatocellular Carcinoma: Principles of Management. **2019**, 123-138 1
- 165 Role of Interventional Radiology in Management of Gastrointestinal Cancers and Neuroendocrine Tumors. **2019**, 551-572
- 164 Anti-angiogenics in Hepatocellular Cancer Therapy. **2019**, 435-446
- 163 Transarterial Therapies. **2019**, 135-150
- 162 Hepatocellular Carcinoma. **2019**, 207-234

- 161 Transcatheter embolization of hepatocellular carcinoma with epirubicin-loaded DC beads in Chinese patients.. **2019**, 8, 279-289
- 160 Efficacy and safety of CalliSpheres drug-eluting beads transarterial chemoembolization in patients with secondary liver cancer: a preliminary result from CTILC study.. **2019**, 8, 1199-1216
- 159 Efficacy and safety of a monodisperse solid-in-oil-in-water emulsion in transcatheter arterial chemoembolization in a rabbit VX2 tumor model.
- 158 Regional Therapies in Hepatocellular Carcinoma and Cholangiocarcinoma. **2020**, 311-322
- 157 Chemoembolization for Colorectal Liver Metastases. **2020**, 507-518
- 156 Predictive model for acute abdominal pain after transarterial chemoembolization for liver cancer. **2020**, 26, 4442-4452 1
- 155 A Transarterial Chemoembolization of Balloon-Occluded Alternate Infusions of Cisplatin and Gelatin Particles for Hepatocellular Carcinoma: A Phase I/II Multicenter Prospective Study of Safety and Efficacy. **2021**, 0
- 154 The update on transcatheter arterial chemoembolization using drug-eluting beads: Optimization for best response. **2021**, 10, 161-164 1
- 153 Comparison of metabolic and immunologic responses to transarterial chemoembolization with different chemoembolic regimens in a rabbit VX2 liver tumor model. **2021**, 1 1
- 152 A Four-Step Cascade Drug-Release Management Strategy for Transcatheter Arterial Chemoembolization (TACE) Therapeutic Applications. **2021**, 13, 0
- 151 Portal Vein Damage after DEB-TACE and Lipiodol-TACE: Based on Evaluation by Computed Tomography during Arterial Portography. **2021**, 6, 93-101
- 150 Therapy of Intermediate-Stage Hepatocellular Carcinoma: Current Evidence and Clinical Practice. **2020**, 37, 456-465 3
- 149 Treatment Options for Early-Stage Hepatocellular Carcinoma. **2020**, 37, 448-455
- 148 Comparison of transarterial bland and chemoembolization for neuroendocrine tumours: a systematic review and meta-analysis. **2020**, 27, e537-e546 1
- 147 Embolization Therapy for Liver Cancer. **2020**, 667-672
- 146 Progress in research of hepatocellular carcinoma with tumor thrombus. **2019**, 27, 1239-1247
- 145 Chemoembolization for Hepatocellular Carcinoma. **2020**, 282-286.e2
- 144 Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma. **2020**, 26, S1-S40 4

143	Physics and Physiology of Transarterial Chemoembolization and Drug-Eluting Beads for Liver Tumors. 2020 , 29-42	
142	Liver Cancer. 2020 , 341-368	
141	Hepatocellular Carcinoma: Western Experience. 2020 , 81-118	
140	Transarterial Chemoembolization with LC Bead LUMI followed by Stereotactic Body Radiation Therapy in Treatment of Hepatocellular Carcinoma.. 2022 , 7, 100830	
139	Impact of cone-beam computed tomography with automated feeder detection software on the survival outcome of patients with hepatocellular carcinoma during treatment with conventional transarterial chemoembolization. 2021 , 21, 419	2
138	Oncological care for the patients with hepatocellular carcinoma in COVID-19 pandemic. 2020 , 226-231	
137	Transarterial Chemoembolisation and Combined Therapy. 2021 , 283-317	
136	Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation. 2020 , 24, 1-264	2
135	Is Transarterial Chemoembolization Only Treatment Option in Patients with Intermediate Stage of Hepatocellular Carcinoma?: in Perspectives of Surgery. 2020 , 20, 113-119	
134	Onkologische Embolisation. 2021 , 409-504	
133	Updates in the management of hepatocellular carcinoma. 2011 , 7, 16-24	37
132	Drug-eluting microspheres transarterial chemoembolization (DEM TACE) in patients with liver metastases. Pilot study. 2011 , 76, 26-32	6
131	What's New in Transarterial Therapies for Hepatocellular Carcinoma?. 2012 , 5, S14-9	
130	A comparative study between Embosphere(®) and conventional transcatheter arterial chemoembolization for treatment of unresectable liver metastasis from GIST. 2014 , 26, 124-31	10
129	Current management of hepatocellular carcinoma. 2014 , 10, 153-61	70
128	Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma. 2013 , 9, 1-24	5
127	Hepatocellular Carcinoma With Intra-atrial Extension Responding to Transarterial Chemoembolization via the Right Hepatic and Right Inferior Phrenic Arteries. 2014 , 7, 111-6	4
126	Doxorubicin-eluting beads versus conventional transarterialchemoembolization for the treatment of hepatocellular carcinoma: a meta-analysis. 2014 , 7, 3892-903	13

125	Novel imaging biomarkers of response to transcatheter arterial chemoembolization in hepatocellular carcinoma patients. 2015 , 27, 611-26	
124	Intraarterial Liver-Directed Therapies: The Role of Interventional Oncology. 2017 , 17, 412-416	6
123	Drug-eluting bead transarterial chemoembolization is efficient and well-tolerated in treating elderly Chinese hepatocellular carcinoma patients. 2018 , 11, 4867-4878	4
122	Antitumor properties of arsenic trioxide-loaded CalliSpheres microspheres by transarterial chemoembolization in VX2 liver tumor rabbits: suppression of tumor growth, angiogenesis, and metastasis and elongation of survival. 2020 , 12, 5511-5524	1
121	Update on the Diagnosis and Treatment of Hepatocellular Carcinoma. 2020 , 16, 506-516	3
120	Long Term Survival Analysis in a Cohort of 125 Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using Small Drug Eluting Beads. <i>CardioVascular and Interventional Radiology</i> , 2021 , 45, 54	2.7
119	Downstaging Conversion Therapy in Patients With Initially Unresectable Advanced Hepatocellular Carcinoma: An Overview. 2021 , 11, 772195	1
118	The importance of liver functional reserve in the non-surgical treatment of Hepatocellular Carcinoma. 2021 ,	2
117	Stereotactic body radiation therapy for primary liver tumors: An effective liver-directed therapy in the toolbox. 2021 ,	0
116	Hepatocellular carcinoma locoregional therapies: Outcomes and future horizons. 2021 , 27, 7462-7479	2
115	Combination therapies plus transarterial chemoembolization in hepatocellular carcinoma: a snapshot of clinical trial progress. 2021 , 1-13	1
114	BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update. 2021 ,	127
113	Lokale Tumorablation und Selektive Interne Radiotherapie ff. Patienten mit Metastasierten Neuroendokrinen Tumoren ¶ Interventionelle Tumorthapieverfahren. 2021 , 44, 344-354	0
112	Donafenib-Loaded Callispheres Beads Embolization in a VX2 Liver Tumor: Investigating Efficacy, Safety, and Improvement of Tumor Angiogenesis After Embolization. 2021 , 8, 1525-1535	
111	Limitations and Possibilities of Transarterial Chemotherapeutic Treatment of Hepatocellular Carcinoma. 2021 , 22,	0
110	Hepatic Interventional Oncology. 2022 , 415-441	
109	Effect of drug-eluting bead transarterial chemoembolization loaded with cisplatin on normal dogs. 2021 ,	0
108	Peritumoral portal enhancement during transarterial chemoembolization: a potential prognostic factor for patients with hepatocellular carcinoma. 2021 , 2841851211041832	0

107	Role of Pretransplant Treatments for Patients with Hepatocellular Carcinoma Waiting for Liver Transplantation.. 2022 , 14,	0
106	Efficacy, safety, and prognostic factors of drug-eluting beads transarterial chemoembolization using CalliSpheres in treating huge hepatocellular carcinoma patients.. 2022 ,	0
105	Clinical effects and safety of different transarterial chemoembolization methods for bridging and palliative treatments in hepatocellular carcinoma.. 2022 , 1	1
104	Quantitative washout in patients with hepatocellular carcinoma undergoing TACE: an imaging biomarker for predicting prognosis?. 2022 , 22, 5	1
103	Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment.. 2022 , 12, 822507	0
102	The trends and efficacy of operation in the treatment of hepatocellular carcinoma.. 2022 , 11, 148-159	
101	S3-Leitlinie: Diagnostik und Therapie des hepatozellulären Karzinoms. 2022 , 60, e56-e130	0
100	S3-Leitlinie: Diagnostik und Therapie des hepatozellulären Karzinoms [Kurzversion 2.00] Juni 2021, AWMF-Registernummer: 032-053OL. 2022 , 60, 81-107	
99	Hepatocellular carcinoma: Neoadjuvant systemic and local treatment concepts to improve resectability rates and oncological outcome. 2022 , 15, 5	0
98	MicroRNAs Related to TACE Treatment Response: A Review of the Literature from a Radiological Point of View.. 2022 , 12,	1
97	Prevalence and clinical significance of clinically evident portal hypertension in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.. 2021 ,	2
96	Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Camrelizumab Compared With Conventional Transarterial Chemoembolization Plus Camrelizumab for Unresectable Hepatocellular Carcinoma.. 2022 , 29, 10732748221076806	0
95	Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Unresectable Hepatocellular Carcinoma: Efficacy and Systemic Immune Response.. 2022 , 13, 847601	1
94	Tumor Burden in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Head-to-Head Comparison of Current Scoring Systems.. 2022 , 12, 850454	0
93	Comparison of Clinical Efficacy and Safety between 70-150 µm and 100-300 µm Doxorubicin Drug-Eluting Bead Transarterial Chemoembolization for Hepatocellular Carcinoma.. 2022 , 12,	1
92	Acetazolamide enhanced drug-eluting beads: manipulating the hepatocellular carcinoma microenvironment.. 2022 , 1-5	
91	Comparison of tumor response following conventional versus drug-eluting bead transarterial chemoembolization in early- and very early-stage hepatocellular carcinoma.. 2022 , 5, 10-14	1
90	Use of chemotherapy to treat hepatocellular carcinoma.. 2022 , 16,	1

- 89 [Transarterial chemoembolization of hepatocellular carcinoma].. **2022**, 62, 225 0
- 88 Neoadjuvant approaches in hepatocellular carcinoma: There's no time like the present.. **2022**, 0
- 87 POLYETHYLENE-GLYCOL DRUG-ELUTING EMBOLIC MICROSPHERES LOADED WITH DOXORUBICIN FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA: FEASIBILITY, SAFETY AND PHARMACOKINETIC STUDY.. **2022**, 0
- 86 Diagnostik und intraarterielle Therapien primärer Lebertumoren. **2022**, 28, 308-317
- 85 Transarterial Chemoembolization Combined With Tyrosine Kinase Inhibitors for Intermediate-Stage Hepatocellular Carcinoma, What Else Can We Do?. **2022**, 12, 824799 0
- 84 Y Radioembolization versus Drug-eluting Bead Chemoembolization for Unresectable Hepatocellular Carcinoma: Results from the TRACE Phase II Randomized Controlled Trial.. **2022**, 211806 2
- 83 Treatment efficacy and safety of drug-eluting beads transarterial chemoembolization versus conventional transarterial chemoembolization in hepatocellular carcinoma patients with arterioportal fistula.. **2022**, 23, 89-95 0
- 82 Fully automated AI-based splenic segmentation for predicting survival and estimating the risk of hepatic decompensation in TACE patients with HCC.. **2022**, 1 0
- 81 Conventional Transarterial Chemoembolization Versus Drug-Eluting Beads in Patients with Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.. **2021**, 13, 1
- 80 Efficacy of Superselective Conventional Transarterial Chemoembolization Using Guidance Software for Hepatocellular Carcinoma within Three Lesions Smaller Than 3 cm.. **2021**, 13, 1
- 79 Efficacy and Safety of 4 Fractions of Carbon-Ion Radiation Therapy for Hepatocellular Carcinoma: A Prospective Study.. **2022**, 11, 61-74 0
- 78 Liver MRI and clinical findings to predict response after drug eluting bead transarterial chemoembolization in hepatocellular carcinoma.. **2021**, 11, 24076 2
- 77 Neoadjuvant treatment strategies for hepatocellular carcinoma.. **2021**, 13, 1550-1566 2
- 76 Safety and Long-Term Survival Outcome in Patients With Unresectable Barcelona Clinic Liver Cancer (BCLC) Stages C and D Advanced Hepatocellular Carcinoma Treated With 40 Gy Drug-Eluting Bead Transcatheter Arterial Chemoembolization.. **2022**, 14, e24047 0
- 75 Data_Sheet_1.PDF. **2020**,
- 74 Updates on clinical trials for the management of hepatocellular carcinoma. **2022**, 259-273
- 73 Recent Trends and In-Hospital Mortality of Transarterial Chemoembolization (TACE) in Germany: A Systematic Analysis of Hospital Discharge Data between 2010 and 2019.. **2022**, 14,
- 72 Systematic Review and Pharmacokinetic Meta-analysis of Doxorubicin Exposure in Transcatheter Arterial Chemoembolization and Doxorubicin-Eluted Beads Chemoembolization for Treatment of Unresectable Hepatocellular Carcinoma.. **2022**,

- 71 Phase 0 study of vandetanib-eluting radiopaque embolics as a pre-operative embolization treatment in patients with resectable liver malignancies.. **2022,**
- 70 Safety and efficacy of drug-eluting microspheres chemoembolization under cone beam computed tomography control in patients with early and intermediate stage hepatocellular carcinoma.. **2022,**
- 69 Interventional Radiology of the Liver. **2015,** 1498-1519
- 68 Local and Regional Therapies for Hepatocellular Carcinoma and Future Combinations. **2022,** 14, 2469 1
- 67 What Is the Most Suitable Agent Combined With Apatinib for Transarterial Chemoembolization Treatment in Advanced Hepatocellular Carcinoma Patients? A Systematic Review and Network Meta-analysis. **2022,** 12, 0
- 66 Combination TACE and SBRT for Unresectable Single Large HCC: Results from a Prospective Phase II Trial. **2022,** 0
- 65 Hepatobiliary Cancers. **2022,** 311-355
- 64 IR Liver-Directed Therapies for HCC. **2021,** 1-12
- 63 Endovascular Procedures in Cancer Patients. **2022,** 467-499
- 62 Hepatosellüler Karsinomda İyileşebilir Mikroküpler ile Yapılan Transarteriyel Kemoembolizasyonun Etkinliği Tek Merkez Deneyimi.
- 61 Conventional or drug-eluting beads? Randomized study of chemo-embolization for hepatocellular carcinoma: JIVROSG-1302. 0
- 60 Idarubicin-Loaded DEB-TACE plus Lenvatinib versus Lenvatinib for patients with advanced hepatocellular carcinoma: A propensity score-matching analysis.
- 59 Transparent Liver Tumor as an Ex Vivo Model for Transarterial Chemoembolization (TACE).
- 58 Sorafenib plus drug-eluting bead transarterial chemoembolization for early intrahepatic stage-progressed advanced hepatocellular carcinoma refractory to conventional transarterial chemoembolization.
- 57 Intraarterial Therapies for the Management of Hepatocellular Carcinoma. **2022,** 14, 3351 1
- 56 Embolization therapy with microspheres for the treatment of liver cancer: State-of-the-art of clinical translation. **2022,** 3
- 55 Animal Models of Hepatocellular Carcinoma for Local-Regional Intraarterial Therapies. **2022,** 4,
- 54 Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization Combining Immune Checkpoint Inhibitors in Unresectable Intrahepatic Cholangiocarcinoma: A Propensity Score Matching Analysis. 13, 0

- 53 Interventional Imaging in the Oncologic Patient. **2023**, 670-680
- 52 Combination approaches in hepatocellular carcinoma: How systemic treatment can benefit candidates to locoregional modalities. **2022**, 28, 3573-3585
- 51 Pharmacokinetic study comparing doxorubicin concentrations after chemoembolization or intravenous administration in dogs with naturally occurring nonresectable hepatic carcinoma.
- 50 Safety and Efficacy of Drug-Eluting Beads Trans-Arterial Chemoembolization for Hepatocellular Carcinoma in Taiwan (SERENADE-T). Volume 9, 811-821
- 49 Interventional radiology meets immuno-oncology for hepatocellular carcinoma. **2022**, 2
- 48 Low bone mineral density is a prognostic factor for elderly patients with HCC undergoing TACE: results from a multicenter study.
- 47 Evaluation of D-TACE combined with endovascular brachytherapy for HCC with MPVTT. 12,
- 46 IR Liver-Directed Therapies for HCC. **2022**, 147-158 ○
- 45 Zytostatikabeschichtete Beads. **2022**, 1-8 ○
- 44 Locoregional Therapies for Hepatocellular Carcinoma. **2022**, ○
- 43 Hepatocellular carcinoma. **2022**, 13
- 42 Retrospective Study of the Efficacy and Safety of Chemoembolization with Drug-Eluting Microspheres Combined with Intra-Arterial Infusion of Bevacizumab for Unresectable Hepatocellular Carcinoma. Volume 9, 973-985 ○
- 41 The efficacy and safety of conventional transcatheter arterial chemoembolization combined with PD-1 inhibitor and anti-angiogenesis tyrosine kinase inhibitor treatment for patients with unresectable hepatocellular carcinoma: a real-world comparative study. 12, ○
- 40 Drug Delivery in Transarterial Chemoembolization of Hepatocellular Carcinoma: Ex vivo Evaluation Using Transparent Tissue Imaging. **2022**, ○
- 39 Endovascular Treatments of Hepatocellular Carcinoma. **2023**, 71-79 ○
- 38 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. **2022**, 28, 583-705 3
- 37 Cost-effectiveness analysis of drug-eluting beads and conventional transarterial chemoembolization in the treatment of hepatocellular carcinoma. 10, ○
- 36 Exploring a four-gene risk model based on doxorubicin resistance-associated lncRNAs in hepatocellular carcinoma. 13, ○

35	Nonsurgical Treatment for Localised Hepatocellular Carcinoma. 69-75	0
34	2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. 2022 , 23, 1126	4
33	Conventional vs. Drug-Eluting Beads Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Propensity Score Weighted Comparison of Efficacy and Safety. 2022 , 14, 5847	0
32	ACR Appropriateness Criteria: Management of Liver Cancer: 2022 Update. 2022 , 19, S390-S408	0
31	Evaluation of Transarterial Chemoembolization Protocol with Drug-Eluting Beads in Combination with Lipiodol for Hepatocellular Carcinoma: A Single-Center Controlled Study. 2022 , 2022, 1-10	0
30	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma.	0
29	Transarterial chemoembolisation plus I125 seeds implantation for people with unresectable hepatocellular carcinoma. 2022 , 2022,	0
28	Six-Year Evaluation of Same-Day Discharge following Conventional Transarterial Chemoembolization of Hepatocellular Carcinoma. 2022 ,	0
27	Pathogenesis and Current Treatment Strategies of Hepatocellular Carcinoma. 2022 , 10, 3202	1
26	Parthenolide induces rapid thiol oxidation that leads to ferroptosis in hepatocellular carcinoma cells. 4,	1
25	Drug-eluting Microspheres Compared to Conventional Transarterial Chemoembolization as First Line Treatment for Unresectable Hepatocellular Carcinoma: A Single-center Retrospective Cost-utility Analysis.	0
24	2022 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for Transarterial Therapy of Hepatocellular Carcinoma: What's New?. 2023 , 24, 6	0
23	Prognostic value of combined pre- and postoperative albumin-to-alkaline phosphatase ratio for patients with hepatocellular carcinoma undergoing trans-catheter chemoembolisation. 2023 ,	0
22	Efficacy and Safety of Combined Ethanol-Lipiodol Mixture and Drug-Eluting Bead TACE for Large HCC. Volume 10, 81-90	0
21	Prinzipien der nicht-chirurgischen lokoregionellen Therapie. 2023 , 1-10	0
20	Safety, Efficacy and Distribution of Doxorubicin Loaded Radiopaque Beads in Chemoembolization in Intermediate Stage Hepatocellular Carcinoma (HCC) with Correlation with Local Response.	0
19	Complications Related to Transarterial Treatment of Hepatocellular Carcinoma: A Comprehensive Review. 24,	0
18	Multifunctional nanoplatforms application in the transcatheter chemoembolization against hepatocellular carcinoma. 2023 , 21,	0

- 17 Preoperative sintilimab plus transarterial chemoembolization for hepatocellular carcinoma exceeding the Milan criteria: A phase II trial. **2023**, 7, e0054-e0054 ○
- 16 Therapeutic options in hepatocellular carcinoma: a comprehensive review. ○
- 15 Management of Hepatocellular Carcinoma. **2023**, 158, 410 ○
- 14 Quantitative Analysis of Signal Heterogeneity in the Hepatobiliary Phase of Pretreatment Gadoteric Acid-Enhanced MRI as a Prognostic Imaging Biomarker in Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma. **2023**, 15, 1238 ○
- 13 Textbook Outcome After Trans-arterial Chemoembolization for Hepatocellular Carcinoma. **2023**, 46, 449-459 ○
- 12 Clinical consensus statement: Establishing the roles of locoregional and systemic therapies for the treatment of intermediate-stage hepatocellular carcinoma in Canada. **2023**, 115, 102526 ○
- 11 Use of doxorubicin-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein invasion: a prospective study. **2023**, 23, 166-176 ○
- 10 Non-Surgical Locoregional Therapies Alone or in Combination with Systemic Therapy in Patients with Hepatocellular Carcinoma. **2023**, 15, 1748 ○
- 9 Creating and Testing a Model to Predict Postoperative Discomfort in Patients with Hepatocellular Carcinoma Receiving Transarterial Chemoembolisation. **2023**, 23, ○
- 8 Efficacy and Safety of Distal Radial Access for Transcatheter Arterial Chemoembolization (TACE) of the Liver. **2023**, 13, 640 ○
- 7 S3-Leitlinie Diagnostik und Therapie biliärer Karzinome. **2023**, 61, 420-440 ○
- 6 Targeting angiogenesis in oncology, ophthalmology and beyond. ○
- 5 S3-Leitlinie Diagnostik und Therapie biliärer Karzinome [Langversion]. **2023**, 61, e92-e156 ○
- 4 TACE for HCC : A critical review of the 2021 CIRSE recommendations with presentation of a technique for a degradable starch microsphere TACE. ○
- 3 Interventional Oncology and Immuno-Oncology: Current Challenges and Future Trends. **2023**, 24, 7344 ○
- 2 In vitro comparative study of multimodal imaging nano-assembled microspheres with two clinical drug-eluting beads loaded with doxorubicin. **2023**, 30, ○
- 1 Optimal Treatment for Small HCC ($\leq 3\text{ cm}$): Resection, Liver Transplantation, or Locoregional Therapy?. **2023**, 100781 ○